0001907982 December 31 2023 Q3 true http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent 0001907982 2023-01-01 2023-09-30 0001907982 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001907982 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001907982 2023-11-08 xbrli:shares 0001907982 2023-09-30 iso4217:USD 0001907982 2022-12-31 iso4217:USD xbrli:shares 0001907982 2023-07-01 2023-09-30 0001907982 2022-07-01 2022-09-30 0001907982 2022-01-01 2022-09-30 0001907982 us-gaap:CommonStockMember srt:ScenarioPreviouslyReportedMember 2023-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001907982 srt:ScenarioPreviouslyReportedMember 2023-06-30 0001907982 us-gaap:CommonStockMember srt:RestatementAdjustmentMember 2023-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2023-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001907982 srt:RestatementAdjustmentMember 2023-06-30 0001907982 us-gaap:CommonStockMember 2023-06-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001907982 us-gaap:RetainedEarningsMember 2023-06-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001907982 2023-06-30 0001907982 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001907982 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001907982 us-gaap:CommonStockMember 2023-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001907982 us-gaap:RetainedEarningsMember 2023-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001907982 us-gaap:PreferredStockMember srt:ScenarioPreviouslyReportedMember 2022-06-30 0001907982 us-gaap:CommonStockMember srt:ScenarioPreviouslyReportedMember 2022-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-06-30 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001907982 srt:ScenarioPreviouslyReportedMember 2022-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:PreferredStockMember 2022-06-30 0001907982 us-gaap:CommonStockMember srt:RestatementAdjustmentMember 2022-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2022-06-30 0001907982 srt:RestatementAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001907982 srt:RestatementAdjustmentMember 2022-06-30 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:PreferredStockMember 2022-06-30 0001907982 us-gaap:CommonStockMember qbts:PreviouslyReportedPriorToReverseRecapitalizationMember 2022-06-30 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:RetainedEarningsMember 2022-06-30 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:PreferredStockMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:CommonStockMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:RetainedEarningsMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember 2022-06-30 0001907982 us-gaap:PreferredStockMember 2022-06-30 0001907982 us-gaap:CommonStockMember 2022-06-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001907982 us-gaap:RetainedEarningsMember 2022-06-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001907982 2022-06-30 0001907982 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001907982 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001907982 us-gaap:CommonStockMember qbts:EquityLineOfCreditMember 2022-07-01 2022-09-30 0001907982 qbts:EquityLineOfCreditMember us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001907982 qbts:EquityLineOfCreditMember 2022-07-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember 2022-07-01 2022-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001907982 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001907982 us-gaap:PreferredStockMember 2022-09-30 0001907982 us-gaap:CommonStockMember 2022-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001907982 us-gaap:RetainedEarningsMember 2022-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001907982 2022-09-30 0001907982 us-gaap:CommonStockMember srt:ScenarioPreviouslyReportedMember 2022-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001907982 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001907982 us-gaap:CommonStockMember srt:RestatementAdjustmentMember 2022-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2022-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001907982 srt:RestatementAdjustmentMember 2022-12-31 0001907982 us-gaap:CommonStockMember 2022-12-31 0001907982 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001907982 us-gaap:RetainedEarningsMember 2022-12-31 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001907982 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001907982 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001907982 us-gaap:PreferredStockMember srt:ScenarioPreviouslyReportedMember 2021-12-31 0001907982 us-gaap:CommonStockMember srt:ScenarioPreviouslyReportedMember 2021-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2021-12-31 0001907982 srt:ScenarioPreviouslyReportedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001907982 srt:ScenarioPreviouslyReportedMember 2021-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:PreferredStockMember 2021-12-31 0001907982 us-gaap:CommonStockMember srt:RestatementAdjustmentMember 2021-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001907982 srt:RestatementAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001907982 srt:RestatementAdjustmentMember 2021-12-31 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:PreferredStockMember 2021-12-31 0001907982 us-gaap:CommonStockMember qbts:PreviouslyReportedPriorToReverseRecapitalizationMember 2021-12-31 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:RetainedEarningsMember 2021-12-31 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001907982 qbts:PreviouslyReportedPriorToReverseRecapitalizationMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:PreferredStockMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:CommonStockMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001907982 qbts:RevisionOfPriorPeriodReverseRecapitalizationAdjustmentMember 2021-12-31 0001907982 us-gaap:PreferredStockMember 2021-12-31 0001907982 us-gaap:CommonStockMember 2021-12-31 0001907982 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001907982 us-gaap:RetainedEarningsMember 2021-12-31 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001907982 2021-12-31 0001907982 us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001907982 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001907982 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001907982 us-gaap:CommonStockMember qbts:EquityLineOfCreditMember 2022-01-01 2022-09-30 0001907982 qbts:EquityLineOfCreditMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001907982 qbts:EquityLineOfCreditMember 2022-01-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001907982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001907982 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001907982 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001907982 qbts:LincolnParkPurchaseAgreementMember 2023-01-01 2023-09-30 0001907982 qbts:LincolnParkPurchaseAgreementMember 2022-01-01 2022-09-30 qbts:facility 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-04-13 0001907982 qbts:DebtInstrumentTrancheOneMember us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-04-13 0001907982 us-gaap:LineOfCreditMember qbts:DebtInstrumentTrancheThreeMember qbts:TermLoanMember 2023-04-13 0001907982 2022-06-16 xbrli:pure 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-04-13 2023-04-13 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-07-01 2023-09-30 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-01-01 2023-09-30 0001907982 us-gaap:NotesPayableOtherPayablesMember qbts:SIFLoanMember 2020-11-20 iso4217:CAD 0001907982 qbts:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001907982 us-gaap:FairValueInputsLevel2Member qbts:PrivateWarrantsMember 2023-09-30 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001907982 srt:ScenarioPreviouslyReportedMember 2023-09-30 0001907982 srt:RestatementAdjustmentMember 2023-09-30 0001907982 srt:ScenarioPreviouslyReportedMember 2023-07-01 2023-09-30 0001907982 srt:RestatementAdjustmentMember 2023-07-01 2023-09-30 0001907982 srt:ScenarioPreviouslyReportedMember 2022-07-01 2022-09-30 0001907982 srt:RestatementAdjustmentMember 2022-07-01 2022-09-30 0001907982 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-09-30 0001907982 srt:RestatementAdjustmentMember 2023-01-01 2023-09-30 0001907982 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-09-30 0001907982 srt:RestatementAdjustmentMember 2022-01-01 2022-09-30 0001907982 2022-08-05 0001907982 qbts:DCPMCapitalIncClassACommonStockMember 2022-08-05 2022-08-05 0001907982 qbts:DPCMCapitalIncStockholdersMember qbts:DCPMCapitalIncClassACommonStockMember 2022-08-05 2022-08-05 0001907982 qbts:DCPMCapitalCorpIncClassBCommonStockMember qbts:DPCMCapitalIncStockholdersMember 2022-08-05 2022-08-05 0001907982 qbts:DCPMCapitalCorpIncClassBCommonStockMember qbts:DPCMCapitalIncStockholdersMember 2022-08-05 0001907982 qbts:DWaveSystemsIncStockholdersMember 2022-08-05 2022-08-05 0001907982 2022-02-07 0001907982 us-gaap:PrivatePlacementMember 2022-02-07 2022-02-07 0001907982 2022-08-02 0001907982 qbts:QCaaSMember 2023-07-01 2023-09-30 0001907982 qbts:QCaaSMember 2022-07-01 2022-09-30 0001907982 qbts:ProfessionalServicesMember 2023-07-01 2023-09-30 0001907982 qbts:ProfessionalServicesMember 2022-07-01 2022-09-30 0001907982 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0001907982 us-gaap:ProductAndServiceOtherMember 2022-07-01 2022-09-30 0001907982 us-gaap:TransferredOverTimeMember 2023-07-01 2023-09-30 0001907982 us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0001907982 us-gaap:TransferredAtPointInTimeMember 2023-07-01 2023-09-30 0001907982 us-gaap:TransferredAtPointInTimeMember 2022-07-01 2022-09-30 0001907982 qbts:QCaaSMember 2023-01-01 2023-09-30 0001907982 qbts:QCaaSMember 2022-01-01 2022-09-30 0001907982 qbts:ProfessionalServicesMember 2023-01-01 2023-09-30 0001907982 qbts:ProfessionalServicesMember 2022-01-01 2022-09-30 0001907982 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0001907982 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-09-30 0001907982 us-gaap:TransferredOverTimeMember 2023-01-01 2023-09-30 0001907982 us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0001907982 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-09-30 0001907982 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0001907982 country:US 2023-07-01 2023-09-30 0001907982 country:US 2022-07-01 2022-09-30 0001907982 country:JP 2023-07-01 2023-09-30 0001907982 country:JP 2022-07-01 2022-09-30 0001907982 country:DE 2023-07-01 2023-09-30 0001907982 country:DE 2022-07-01 2022-09-30 0001907982 country:CH 2023-07-01 2023-09-30 0001907982 country:CH 2022-07-01 2022-09-30 0001907982 qbts:OtherGeographicalAreasMember 2023-07-01 2023-09-30 0001907982 qbts:OtherGeographicalAreasMember 2022-07-01 2022-09-30 0001907982 country:US 2023-01-01 2023-09-30 0001907982 country:US 2022-01-01 2022-09-30 0001907982 country:JP 2023-01-01 2023-09-30 0001907982 country:JP 2022-01-01 2022-09-30 0001907982 country:DE 2023-01-01 2023-09-30 0001907982 country:DE 2022-01-01 2022-09-30 0001907982 country:CH 2023-01-01 2023-09-30 0001907982 country:CH 2022-01-01 2022-09-30 0001907982 qbts:OtherGeographicalAreasMember 2023-01-01 2023-09-30 0001907982 qbts:OtherGeographicalAreasMember 2022-01-01 2022-09-30 0001907982 qbts:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001907982 qbts:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember qbts:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember qbts:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerCMember 2023-07-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerCMember 2022-07-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerDMember 2023-07-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerDMember 2022-07-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerEMember 2023-07-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerEMember 2022-07-01 2022-09-30 0001907982 qbts:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001907982 qbts:CustomerAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember qbts:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember qbts:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerCMember 2023-01-01 2023-09-30 0001907982 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember qbts:CustomerCMember 2022-01-01 2022-09-30 0001907982 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember qbts:FourCustomersMember 2023-01-01 2023-09-30 0001907982 us-gaap:AccountsReceivableMember qbts:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001907982 2023-10-01 2023-09-30 0001907982 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-09-30 0001907982 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001907982 qbts:LabEquipmentMember 2023-09-30 0001907982 qbts:LabEquipmentMember 2022-12-31 0001907982 us-gaap:ComputerEquipmentMember 2023-09-30 0001907982 us-gaap:ComputerEquipmentMember 2022-12-31 0001907982 us-gaap:LeaseholdImprovementsMember 2023-09-30 0001907982 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001907982 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001907982 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001907982 us-gaap:ConstructionInProgressMember 2023-09-30 0001907982 us-gaap:ConstructionInProgressMember 2022-12-31 0001907982 srt:NorthAmericaMember 2023-09-30 0001907982 srt:NorthAmericaMember 2022-12-31 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2023-09-30 0001907982 us-gaap:LineOfCreditMember qbts:TermLoanMember 2022-12-31 0001907982 qbts:TPCGovernmentLoansMember us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001907982 qbts:TPCGovernmentLoansMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001907982 qbts:DirectorsAndOfficersInsuranceFinancingMember us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001907982 qbts:DirectorsAndOfficersInsuranceFinancingMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001907982 qbts:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001907982 qbts:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001907982 us-gaap:NotesPayableOtherPayablesMember qbts:SIFLoanMember 2023-09-30 0001907982 us-gaap:NotesPayableOtherPayablesMember qbts:SIFLoanMember 2022-12-31 0001907982 us-gaap:NotesPayableOtherPayablesMember qbts:SIFLoanMember 2022-09-30 0001907982 us-gaap:LineOfCreditMember qbts:DebtInstrumentRepaymentPeriodOneMember qbts:TermLoanMember 2023-04-13 2023-04-13 0001907982 us-gaap:LineOfCreditMember qbts:DebtInstrumentRepaymentPeriodTwoMember qbts:TermLoanMember 2023-04-13 2023-04-13 0001907982 us-gaap:LineOfCreditMember qbts:DebtInstrumentRepaymentPeriodThreeMember qbts:TermLoanMember 2023-04-13 2023-04-13 0001907982 2023-07-20 0001907982 2023-07-20 2023-07-20 0001907982 qbts:PublicWarrantsMember 2022-08-05 2022-08-05 0001907982 qbts:PrivateWarrantsMember 2022-08-05 2022-08-05 0001907982 2022-08-05 2022-08-05 qbts:day 0001907982 qbts:PreferredStockWarrantsMember 2020-11-30 0001907982 qbts:PreferredStockWarrantsMember 2022-08-05 0001907982 qbts:PreferredStockWarrantsMember 2022-11-28 0001907982 2022-11-28 0001907982 qbts:VestWarrantsMember 2022-11-28 2022-11-28 0001907982 srt:AffiliatedEntityMember 2022-12-31 0001907982 srt:AffiliatedEntityMember 2023-01-01 2023-09-30 0001907982 srt:AffiliatedEntityMember 2023-09-30 0001907982 us-gaap:BeneficialOwnerMember 2023-01-01 2023-09-30 0001907982 2022-01-01 2022-12-31 0001907982 qbts:EquityIncentivePlan2020Member 2023-09-30 0001907982 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001907982 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001907982 us-gaap:EmployeeStockMember 2023-09-30 0001907982 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001907982 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001907982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001907982 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001907982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001907982 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001907982 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001907982 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0001907982 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001907982 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001907982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001907982 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001907982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001907982 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001907982 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001907982 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0001907982 qbts:PublicWarrantsMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001907982 qbts:PublicWarrantsMember us-gaap:WarrantMember 2022-01-01 2022-09-30 0001907982 us-gaap:WarrantMember qbts:PrivateWarrantsMember 2023-01-01 2023-09-30 0001907982 us-gaap:WarrantMember qbts:PrivateWarrantsMember 2022-01-01 2022-09-30 0001907982 qbts:PreferredStockWarrantsMember 2023-01-01 2023-09-30 0001907982 qbts:PreferredStockWarrantsMember 2022-01-01 2022-09-30 0001907982 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001907982 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001907982 qbts:EquityIncentivePlan2022Member 2023-01-01 2023-09-30 0001907982 qbts:EquityIncentivePlan2022Member 2022-01-01 2022-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001907982 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001907982 us-gaap:SubsequentEventMember 2023-10-20 0001907982 us-gaap:SubsequentEventMember 2023-10-20 2023-10-20
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 10-Q/A
________________________
(Mark One)

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023
OR

o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ and ____________
Commission file number 001-41468
________________________
D-WAVE QUANTUM INC.
(Exact name of registrant as specified in its charter)
________________________

Delaware | 88-1068854
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
2650 East Bayshore Road Palo Alto, California | 94303
(Address of Principal Executive Offices) | (Zip Code)

(604) 630-1428
Registrant's telephone number, including area code
(Former name, former address and former fiscal year, if changed since last report)
________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.0001 per share | QBTS | New York Stock Exchange
Warrants, each whole warrant exercisable for 1.4541326 shares of common stock at an exercise price of $11.50 | QBTS.WT | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  | Accelerated filer | o
Non-accelerated filer | x |  | Smaller reporting company | x
|  |  | Emerging growth company | x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of November 8, 2023, the registrant had 113,401,611 shares of common stock at par value $0.0001 outstanding. In addition, there were 46,526,886 exchangeable shares outstanding as of November 8, 2023, which are convertible into shares of common stock on a one for one basis at any time for no consideration.

Table of Contents
Table of Contents

|  | Page
Part I. Financial Information |
Item 1. | D-Wave Quantum Inc. Financial Statements (Unaudited) | 5
| Condensed Consolidated Balance Sheets | 6
| Condensed Consolidated Statements of Operations and Comprehensive Loss | 7
| Condensed Consolidated Statement of Changes in Stockholders’ (Deficit) Equity | 8
| Condensed Consolidated Statements of Cash Flows | 12
| Notes to Condensed Consolidated Financial Statements | 13
Item 2. | D-Wave Quantum Inc. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 35
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 42
Item 4. | Controls and Procedures | 42
Part II. Other Information |
Item 1. | Legal Proceedings | 44
Item 1A. | Risk Factors | 44
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44
Item 3. | Defaults Upon Senior Securities | 44
Item 4. | Mine Safety Disclosures | 44
Item 5. | Other Information | 44
Item 6. | Exhibits | 45
Signatures |  | 46

EXPLANATORY NOTE
D-Wave Quantum Inc. (“D-Wave”, “we”, “our”, “us” or the “Company”) is filing this Amendment No. 1 on Form 10-Q (the "Form 10-Q/A” or “Amendment No. 1”) to amend and restate certain items in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 originally filed with the Securities and Exchange Commission (“SEC”) on November 9, 2023 by the Company (the “Original Form 10-Q”). This Form 10-Q/A restates the Company’s previously issued condensed consolidated financial statements as of and for the three and nine month periods ended September 30, 2023 and 2022. See Note 3 - Restatement of Previously Issued Condensed Consolidated Financial Statements, in Part I, Item 1, Financial Statements, for additional information.
Restatement Background
On January 30, 2024, the Audit Committee of the Board of Directors of the Company, after discussions with the Company's management and its current and former independent registered public accounting firms, determined that the Company’s (i) audited financial statements included in the Company’s original Form 10-K for the periods ended December 31, 2022, 2021, and 2020 (the "Audited Financial Statements"), filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 18, 2023, and (ii) unaudited financial statements included in each of the Company’s Quarterly Reports on Form 10-Q for the periods ending September 30, 2023 (the "Q3 2023 Form 10-Q"), June 30, 2023 (the "Q2 2023 Form 10-Q"), and March 31, 2023 (the "Q1 2023 Form 10-Q," and together with the Q2 2023 Form 10-Q and the Q3 2023 Form 10-Q, the "2023 Form 10-Qs") (the "unaudited Financial Statements," and together with the Audited Financial Statements, the "Financial Statements"), filed with the SEC on November 9, 2023, August 10, 2023, and May 10, 2023, respectively, as well as the Registration Statements on Forms S-1 and S-4 (Registration Nos. 333-269732, 333-267126, 333-267124 and 333-263573) initially filed with the SEC on February 13, 2023, August 29, 2022, August 29, 2022, and March 15, 2022, respectively which include the Financial Statements (collectively, the “Affected Periods”), as well as the relevant portions of any communication which describe or are based on the Financial Statements, should no longer be relied upon. The Company is restating the Financial Statements for the Affected Periods in the Form 10-K/A, filed with the SEC on March 15, 2024, this Form 10-Q/A and amendments to the other 2023 Form 10-Qs (collectively, the “Restatement”).
2

Table of Contents
As described in Item 4.02 of the Company’s Form 8-K filed with the SEC on February 2, 2024, we identified certain misstatements in prior periods’ consolidated financial statements relating to accounting for certain government assistance arrangements originated prior to 2021 in the form of conditionally repayable loans with below-market interest rates (the “Arrangements”).
In connection with the preparation of the financial statements for fiscal year 2023, it was determined that the Arrangements were not properly accounted for. The Company initially accounted for these arrangements by analogizing to IAS 20 and IFRS 9, under which the fair value of the interest rate subsidy is recognized as income and the amount repayable is discounted by imputing a market rate of interest. During the preparation of the financial statements for fiscal year 2023, the Company determined that the debt-like characteristics of the Arrangements placed them in the scope of certain U.S. GAAP guidance that precludes imputation of interest where interest rates are affected by tax attributes or legal restrictions prescribed by a governmental agency. As such, the Company restated other income from government assistance and interest expense on the consolidated statements of operations and research incentives receivable and loans payable on the consolidated balance sheets to eliminate the effect of non-cash interest imputation. An error related to the compound annual growth rate input in the estimation of debt repayment cash flows was also corrected.
Items Amended in this Filing
This Form 10-Q/A amends and restates the following items included in the Original Form 10-Q as appropriate to reflect the Restatement and revision of the relevant periods:
•Part I, Item 1-Financial Statements (Unaudited);
•Part I, Item 2-Management’s Discussion and Analysis of Financial Condition and Results of Operations;
•Part I, Item 4-Controls and Procedures; and
•Part II, Item 1A-Risk Factors.
The Company is including with this Form 10-Q/A currently dated certifications of the Company’s Chief Executive Officer and Chief Financial Officer (Exhibits 31.1, 31.2, 32.1, and 32.2).
Except as discussed above and as further described in Note 3 to the Condensed Consolidated Financial Statements in this Form 10-Q/A, the Company has not modified or updated the disclosures presented in the Original Form 10-Q to reflect events that occurred at a later date or facts that subsequently became known to the Company. Accordingly, forward-looking statements included in this Amendment No.1 may represent management’s views as of the Original Form 10-Q and should not be assumed to be accurate as of any date thereafter. Disclosures not affected by the restatement are unchanged and reflect the disclosures made at the time of the Original Filing. Accordingly, this Amended Form 10-Q should be read in conjunction with our filings with the SEC subsequent to the date on which we filed the Original Filing with the SEC.
3

Table of Contents
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Certain statements in this Quarterly Report on Form 10-Q/A (this “Report”) and in documents incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1933, as amended. Unless otherwise indicated or the context otherwise requires, all references in this Report to the terms “D-Wave” and the “Company” refer to D-Wave Quantum Inc., together with its subsidiaries. Our forward-looking statements include, but are not limited to, statements regarding D-Wave and D-Wave’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “believe”, “may”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “anticipate”, “trend”, “believe”, “estimate”, “predict”, “project”, “potential”, “seem”. “seek”, “future”, “outlook”, “forecast”, “projection”, “continue”, “ongoing”, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this Report may include, for example, statements about:
•D-Wave's future growth and innovations;
•the increased adoption of quantum computing solutions and expansion of related market opportunities and use cases;
•D-Wave's expectations regarding product development and functionality;
•D-Wave’s financial and business performance, including financial projections and business metrics relating to, among other things, QCaaS revenue, cost of revenue, operating losses and cash flows;
•changes in D-Wave’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans;
•the ability of D-Wave’s products and services to meet customers’ compliance and regulatory needs;
•developments and projections relating to D-Wave’s products, competitors and industry;
•the impact of the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, the Israel-Hamas War, and any evolutions thereof, on D-Wave’s business and the actions D-Wave may take in response thereto;
•D-Wave’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
•D-Wave's expectations about the Term Loan (as defined below) providing it sufficient cash runway;
•D-Wave’s expectations about investments in general and administrative areas and research and development capabilities;
•whether warrant holders will exercise their warrants in certain conditions;
•D-Wave’s future capital requirements and sources and uses of cash;
•D-Wave’s ability to obtain funding for its operations and future growth; and
•D-Wave’s business, expansion plans and opportunities.
You should not place undue reliance on these forward-looking statements in making an investment decision. These forward-looking statements are based on information available as of the date of this Report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties and are not predictions of actual performance. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
4

Table of Contents
These forward-looking statements are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability regarding future performance, events or circumstances. Many of the factors affecting actual performance, events and circumstances are beyond the control of D-Wave. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.
Some factors that could cause actual results to differ include:
•anticipated trends, growth rates, and challenges in companies, such as D-Wave, that are engaged in the business of quantum computing and in the markets in which they operate;
•the risk that D-Wave’s securities will not maintain a listing on the New York Stock Exchange (“NYSE”);
•risks related to the uncertainty of the unaudited prospective forecasted financial information;
•risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones;
•unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof;
•the performance of D-Wave’s products and services;
•the effects of competition on D-Wave’s business;
•changes in D-Wave’s business as well as market, financial, political and legal conditions;
•the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all;
•the risk that D-Wave may never achieve or sustain profitability;
•the risk that D-Wave is unable to secure or protect its intellectual property;
•changes in applicable laws or regulations;
•the effect of the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, the Israel-Hamas War, geopolitical events, natural disasters, wars, terrorist acts or a combination of these factors on D-Wave’s business and the economy in general;
•the ability of D-Wave to execute its business model, including market acceptance of its planned products and services;
•D-Wave’s ability to raise capital, including under the Purchase Agreement (as defined below) with Lincoln Park Capital Fund LLC ("Lincoln Park");
•D-Wave's ability to obtain funds under the Term Loan (as defined below);
•the possibility that D-Wave may be negatively impacted by other economic, business, and/or competitive factors;
•risks stemming from inflation;
•any changes to applicable tax laws, including U.S. tax laws; and
•other risks and uncertainties described in Report, including those referenced under the section titled “Risk Factors.”
In addition, statements that “D-Wave believes” and similar statements reflect D-Wave’s beliefs and opinions on the relevant subject. These statements are based upon information available to D-Wave as of the date of this Report, and while D-Wave believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that such party has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
5

Table of Contents
Part I - Financial Information
Item 1. Financial Statements
D-Wave Quantum Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

| As of
| September 30, |  | December 31,
| 2023 |  | 2022
(In thousands, except share and per share data) | (As Restated) |  | (As Restated)
Assets |  |  |
Current assets: |  |  |
Cash | $ | 53,317 |  |  | $ | 7,065 |
Trade accounts receivable, net | 763 |  |  | 757 |
Inventories | 2,244 |  |  | 2,196 |
Prepaid expenses and other current assets | 1,870 |  |  | 3,907 |
Total current assets | 58,194 |  |  | 13,925 |
Property and equipment, net | 1,879 |  |  | 2,294 |
Operating lease right-of-use assets | 8,560 |  |  | 9,133 |
Intangible assets, net | 195 |  |  | 244 |
Other noncurrent assets | 1,351 |  |  | 1,351 |
Total assets | $ | 70,179 |  |  | $ | 26,947 |
Liabilities and stockholders' deficit |  |  |
Current liabilities: |  |  |
Trade accounts payable | $ | 1,541 |  |  | $ | 3,756 |
Accrued expenses and other current liabilities | 9,604 |  |  | 8,640 |
Loans payable, net, current | 30,199 |  |  | 1,863 |
Deferred revenue, current | 2,177 |  |  | 1,781 |
Total current liabilities | 43,521 |  |  | 16,040 |
Warrant liabilities | 1,971 |  |  | 1,892 |
Operating lease liabilities, net of current portion | 6,884 |  |  | 7,301 |
Loans payable, net, noncurrent | 32,830 |  |  | 31,168 |
Deferred revenue, noncurrent | 92 |  |  | 9 |
Total liabilities | $ | 85,298 |  |  | $ | 56,410 |
Commitments and contingencies (Note 12) |  |  |
Stockholders' deficit: |  |  |
Common stock par value $0.0001 per share; 675,000,000 shares authorized at September 30, 2023 and December 31, 2022; 155,288,763 shares and 113,335,530 shares issued and outstanding as of September 30, 2023 and December 31, 2022. | $ | 15 |  |  | $ | 11 |
Additional paid-in capital | 462,385 |  |  | 381,274 |
Accumulated deficit | (467,047) |  |  | (400,346) |
Accumulated other comprehensive loss | (10,472) |  |  | (10,402) |
Total stockholders' deficit | (15,119) |  |  | (29,463) |
Total liabilities and stockholders’ deficit | $ | 70,179 |  |  | $ | 26,947 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

| For the three months ended September 30, |  | For the nine months ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
(In thousands, except share and per share data) | (As Restated) |  | (As Restated) |  | (As Restated) |  | (As Restated)
Revenue | $ | 2,562 |  |  | $ | 1,695 |  |  | $ | 5,852 |  |  | $ | 4,778 |
Cost of revenue | 1,033 |  |  | 654 |  |  | 3,197 |  |  | 1,858 |
Total gross profit | 1,529 |  |  | 1,041 |  |  | 2,655 |  |  | 2,920 |
Operating expenses: |  |  |  |  |  |  |
Research and development | 9,459 |  |  | 7,507 |  |  | 29,922 |  |  | 21,799 |
General and administrative | 8,003 |  |  | 5,925 |  |  | 28,875 |  |  | 13,566 |
Sales and marketing | 2,474 |  |  | 2,773 |  |  | 7,862 |  |  | 5,982 |
Total operating expenses | 19,936 |  |  | 16,205 |  |  | 66,659 |  |  | 41,347 |
Loss from operations | (18,407) |  |  | (15,164) |  |  | (64,004) |  |  | (38,427) |
Other income (expense), net: |  |  |  |  |  |  |
Interest expense | (1,035) |  |  | (633) |  |  | (1,822) |  |  | (2,252) |
Change in fair value of warrant liabilities | 1,433 |  |  | 2,603 |  |  | (79) |  |  | 2,603 |
Government assistance | — |  |  | — |  |  | — |  |  | — |
Change in fair value of Term Loan | 1,701 |  |  | — |  |  | 1,356 |  |  | — |
Term Loan debt issuance costs | (725) |  |  | — |  |  | (2,118) |  |  | — |
Lincoln Park Purchase Agreement issuance costs | — |  |  | (629) |  |  | — |  |  | (629) |
Other income (expense), net | 927 |  |  | 2,173 |  |  | (34) |  |  | 2,782 |
Total other income (expense), net | 2,301 |  |  | 3,514 |  |  | (2,697) |  |  | 2,504 |
Net loss | $ | (16,106) |  |  | $ | (11,650) |  |  | $ | (66,701) |  |  | $ | (35,923) |
Net loss per share, basic and diluted | $ | (0.12) |  |  | $ | (0.10) |  |  | $ | (0.51) |  |  | $ | (0.29) |
Weighted-average shares * used in computing net loss per share, basic and diluted | 133,222,318 |  |  | 116,256,805 |  |  | 131,373,959 |  |  | 122,337,727 |
Comprehensive loss: |  |  |  |  |  |  |
Net loss | $ | (16,106) |  |  | $ | (11,650) |  |  | $ | (66,701) |  |  | $ | (35,923) |
Foreign currency translation adjustment, net of tax | 15 |  |  | 56 |  |  | (70) |  |  | 18 |
Net comprehensive loss | $ | (16,091) |  |  | $ | (11,594) |  |  | $ | (66,771) |  |  | $ | (35,905) |

* Weighted-average shares for the three and nine months ended September 30, 2022 have been retroactively restated to give effect to the Merger.
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (As Restated)
For the Three Months Ended September 30, 2023
(Unaudited)

|  |  |  | Stockholders’ Equity (Deficit)
|  | Common stock |  |  |  |  |  |
(In thousands, except share data) |  |  |  | Shares |  | Amount |  | Additional paid-in capital |  | Accumulated deficit |  | Accumulated other comprehensive loss |  | Total stockholders' equity (deficit)
Balances at June 30, 2023 (as reported) |  |  |  | 128,028,658 |  |  | $ | 12 |  |  | $ | 409,885 |  |  | $ | (427,303) |  |  | $ | (10,487) |  |  | $ | (27,893) |
Cumulative restatement adjustments |  |  |  | — |  |  | — |  |  | — |  |  | (23,638) |  |  | — |  |  | (23,638) |
Balances at June 30, 2023 (as restated) |  |  |  | 128,028,658 |  |  | 12 |  |  | 409,885 |  |  | (450,941) |  |  | (10,487) |  |  | (51,531) |
Exercise of stock options |  |  |  | 786,202 |  |  | — |  |  | 683 |  |  | — |  |  | — |  |  | 683 |
Issuance of common stock in connection with the Purchase Agreement |  |  |  | 26,247,450 |  |  | 3 |  |  | 45,660 |  |  | — |  |  | — |  |  | 45,663 |
Issuance of common stock in connection with the ESPP |  |  |  | 226,453 |  |  | — |  |  | 273 |  |  |  |  |  |  | 273 |
Stock-based compensation |  |  |  | — |  |  | — |  |  | 5,884 |  |  | — |  |  | — |  |  | 5,884 |
Foreign currency translation adjustment, net of tax |  |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |  |  | 15 |
Net loss |  |  |  | — |  |  | — |  |  | — |  |  | (16,106) |  |  | — |  |  | (16,106) |
Balance at September 30, 2023 (as restated) |  |  |  | 155,288,763 |  |  | $ | 15 |  |  | $ | 462,385 |  |  | $ | (467,047) |  |  | $ | (10,472) |  |  | $ | (15,119) |

The accompanying notes are an integral part of these condensed consolidated financial statements.
8

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (As Restated)
For the Three Months Ended September 30, 2022
(Unaudited)

| Stockholders’ Equity (Deficit)
| Non-redeemable convertible preferred stock |  | Common stock |  | Additional paid-in capital |  | Accumulated deficit |  | Accumulated other comprehensive loss |  | Total stockholders' equity (deficit)
(In thousands, except share data) | Shares |  | Amount |  | Shares |  | Amount |  |  |  |
Balances at June 30, 2022 (as reported) | 137,765,828 |  |  | $ | 189,881 |  |  | 3,341,327 |  |  | $ | 2,811 |  |  | $ | 147,754 |  |  | $ | (350,697) |  |  | $ | (10,481) |  |  | $ | (20,732) |
Cumulative restatement adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (20,220) |  |  | — |  |  | (20,220) |
Balances at June 30, 2022 (as restated) | 137,765,828 |  |  | 189,881 |  |  | 3,341,327 |  |  | 2,811 |  |  | 147,754 |  |  | (370,917) |  |  | (10,481) |  |  | (40,952) |
Retroactive application of Merger | (15,201,495) |  |  | — |  |  | (368,692) |  |  | (2,811) |  |  | 2,811 |  |  | — |  |  | — |  |  | — |
Adjusted Balances, beginning of period* | 122,564,333 |  |  | 189,881 |  |  | 2,972,635 |  |  | — |  |  | 150,565 |  |  | (370,917) |  |  | (10,481) |  |  | (40,952) |
Issuance of common stock upon conversion of D-Wave Systems preferred stock in connection with the Merger | (122,564,333) |  |  | (189,881) |  |  | 96,764,117 |  |  | 10 |  |  | 189,871 |  |  | — |  |  | — |  |  | — |
Issuance of common stock in connection with the Lincoln Park Purchase Agreement (Note 2) | — |  | — |  | — |  |  | 381,540 |  |  | — |  |  | 3,271 |  |  | — |  |  | — |  |  | 3,271 |
Merger, net of redemptions and transaction costs | — |  | — |  | — |  |  | 4,327,512 |  |  | — |  |  | (16,242) |  |  | — |  |  | — |  |  | (16,242) |
Issuance of common stock in connection with the PIPE Investment | — |  | — |  | — |  |  | 5,816,528 |  |  | 1 |  |  | 39,999 |  |  | — |  |  | — |  |  | 40,000 |
Exercise of warrants | — |  | — |  | — |  |  | 115,025 |  |  | — |  |  | 910 |  |  | — |  |  | — |  |  | 910 |
Stock-based compensation | — |  | — |  | — |  |  |  |  | — |  |  | 1,781 |  |  | — |  |  | — |  |  | 1,781 |
Foreign currency translation adjustment, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 56 |  |  | 56 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (11,650) |  |  | — |  |  | (11,650) |
Balances at September 30, 2022 (as restated) | — |  |  | $ | — |  |  | 110,377,357 |  |  | $ | 11 |  |  | $ | 370,155 |  |  | $ | (382,567) |  |  | $ | (10,425) |  |  | $ | (22,826) |

* Shares of legacy non-redeemable convertible preferred stock and legacy common stock have been retroactively restated to give effect to the Merger.
The accompanying notes are an integral part of these condensed consolidated financial statements.
9

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (As Restated)
For the Nine Months Ended September 30, 2023
(Unaudited)

|  |  |  | Stockholders’ Equity (Deficit)
|  | Common stock |  |  |  |  |  |
(In thousands, except share data) |  |  |  | Shares |  | Amount |  | Additional paid-in capital |  | Accumulated deficit |  | Accumulated other comprehensive loss |  | Total stockholders' equity (deficit)
Balances at December 31, 2022 (as reported) |  |  |  | 113,335,530 |  |  | $ | 11 |  |  | $ | 381,274 |  |  | $ | (376,797) |  |  | $ | (10,402) |  |  | $ | (5,914) |
Cumulative restatement adjustments |  |  |  | — |  |  | — |  |  | — |  |  | (23,549) |  |  | — |  |  | (23,549) |
Balances at December 31, 2022 (as restated) |  |  |  | 113,335,530 |  |  | 11 |  |  | 381,274 |  |  | (400,346) |  |  | (10,402) |  |  | (29,463) |
Exercise of stock options |  |  |  | 2,239,676 |  |  | — |  |  | 1,890 |  |  | — |  |  | — |  |  | 1,890 |
Issuance of common stock in connection with the Purchase Agreement |  |  |  | 39,487,104 |  |  | 4 |  |  | 61,342 |  |  | — |  |  | — |  |  | 61,346 |
Issuance of common stock in connection with the ESPP |  |  |  | 226,453 |  |  | — |  |  | 273 |  |  | — |  |  | — |  |  | 273 |
Stock-based compensation |  |  |  | — |  |  | — |  |  | 17,362 |  |  | — |  |  | — |  |  | 17,362 |
Short-swing profit settlement |  |  |  | — |  |  | — |  |  | 244 |  |  | — |  |  | — |  |  | 244 |
Foreign currency translation adjustment, net of tax |  |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (70) |  |  | (70) |
Net loss (as restated) |  |  |  | — |  |  | — |  |  | — |  |  | (66,701) |  |  | — |  |  | (66,701) |
Balances at September 30, 2023 (as restated) |  |  |  | 155,288,763 |  |  | $ | 15 |  |  | $ | 462,385 |  |  | $ | (467,047) |  |  | $ | (10,472) |  |  | $ | (15,119) |

The accompanying notes are an integral part of these condensed consolidated financial statements.
10

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (As Restated)
For the Nine Months Ended September 30, 2022
(Unaudited)

| Stockholders’ Equity (Deficit)
| Non-redeemable convertible preferred stock |  | Common stock |  | Additional paid-in capital |  | Accumulated deficit |  | Accumulated other comprehensive loss |  | Total stockholders' equity (deficit)
(In thousands, except share data) | Shares |  | Amount |  | Shares |  | Amount |  |  |  |
Balances at December 31, 2021 (as reported) | 137,765,828 |  |  | $ | 189,881 |  |  | 3,166,949 |  |  | $ | 2,610 |  |  | $ | 146,240 |  |  | $ | (325,268) |  |  | $ | (10,443) |  |  | $ | 3,020 |
Cumulative restatement adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (21,376) |  |  | — |  |  | (21,376) |
Balances at December 31, 2021 (as restated) | 137,765,828 |  |  | 189,881 |  |  | 3,166,949 |  |  | 2,610 |  |  | 146,240 |  |  | (346,644) |  |  | (10,443) |  |  | (18,356) |
Retroactive application of Merger | (15,201,495) |  |  | — |  |  | (349,451) |  |  | (2,610) |  |  | 2,610 |  |  | — |  |  | — |  |  | — |
Adjusted Balances, beginning of period* | 122,564,333 |  |  | 189,881 |  |  | 2,817,498 |  |  | — |  |  | 148,850 |  |  | (346,644) |  |  | (10,443) |  |  | (18,356) |
Issuance of common stock upon conversion of D-Wave Systems preferred stock in connection with the Business Combination (Note 4) | (122,564,333) |  |  | (189,881) |  |  | 96,764,117 |  |  | 10 |  |  | 189,871 |  |  | — |  |  | — |  |  | — |
Issuance of common stock in connection with the ELOC (Note 4) | — |  |  | — |  |  | 381,540 |  |  | — |  |  | 3,271 |  |  | — |  |  | — |  |  | 3,271 |
Business Combination, net of redemptions and transaction costs (Note 4) | — |  |  | — |  |  | 4,327,512 |  |  | — |  |  | (16,242) |  |  | — |  |  | — |  |  | (16,242) |
Issuance of common stock in connection with the PIPE Investment (Note 4) | — |  |  | — |  |  | 5,816,528 |  |  | 1 |  |  | 39,999 |  |  | — |  |  | — |  |  | 40,000 |
Old D-Wave exercise of stock options | — |  |  | — |  |  | 155,137 |  |  | — |  |  | 141 |  |  | — |  |  | — |  |  | 141 |
Exercise of warrants | — |  |  | — |  |  | 115,025 |  |  | — |  |  | 910 |  |  | — |  |  | — |  |  | 910 |
Old D-Wave stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | 3,355 |  |  | — |  |  | — |  |  | 3,355 |
Foreign currency translation adjustment, net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 18 |  |  | 18 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (35,923) |  |  | — |  |  | (35,923) |
Balances at September 30, 2022 (as restated) | — |  |  | $ | — |  |  | 110,377,357 |  |  | $ | 11 |  |  | $ | 370,155 |  |  | $ | (382,567) |  |  | $ | (10,425) |  |  | $ | (22,826) |

* Shares of legacy non-redeemable convertible preferred stock and legacy common stock have been retroactively restated to give effect to the Merger.
The accompanying notes are an integral part of these condensed consolidated financial statements.
11

Table of Contents
D-Wave Quantum Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

| Nine months ended September 30,
| 2023 |  | 2022
(in thousands) | (As Restated) |  | (As Restated)
Cash flows from operating activities: |  |  |
Net loss | $ | (66,701) |  |  | $ | (35,923) |
Adjustments to reconcile net loss to cash used in by operating activities: |  |  |
Depreciation and amortization | 828 |  |  | 1,038 |
Stock-based compensation | 17,362 |  |  | 3,355 |
Amortization of operating right-of-use assets | 573 |  |  | 493 |
Non-cash interest expense | 1,745 |  |  | 280 |
Non-cash final fee payment for Venture Loan | — |  |  | 1,808 |
Non-cash Lincoln Park Purchase Agreement issuance costs | — |  |  | 629 |
Change in fair value of Warrant liabilities | 79 |  |  | (2,603) |
Change in fair value of Term Loan | (1,356) |  |  | — |
Debt issuance costs expensed for loans recorded under the fair value option | 993 |  |  | — |
Government assistance | — |  |  | — |
Unrealized foreign exchange loss (gain) | (40) |  |  | (2,707) |
Other non-cash activities | 35 |  |  | 266 |
Change in operating assets and liabilities: |  |  |
Trade accounts receivable | 7 |  |  | 1 |
Research incentives receivable | — |  |  | 1,448 |
Inventories | (235) |  |  | (684) |
Deferred offering costs | — |  |  | 1,250 |
Prepaid expenses and other current assets | 2,035 |  |  | (3,815) |
Trade accounts payable | (2,267) |  |  | 614 |
Accrued expenses and other current liabilities | 965 |  |  | 1,704 |
Deferred revenue | 479 |  |  | (1,051) |
Operating lease liabilities, net of current portion | (412) |  |  | (442) |
Net cash used in operating activities | (45,910) |  |  | (34,339) |
Cash flows from investing activities: |  |  |
Purchase of property and equipment | (141) |  |  | (249) |
Purchase of software | (35) |  |  | (67) |
Net cash used in investing activities | (176) |  |  | (316) |
Cash flows from financing activities: |  |  |
Proceeds from issuance of common stock from the PIPE investment (Note 4) | — |  |  | 40,000 |
Merger, net of redemption and transaction costs (Note 4) | — |  |  | 4,100 |
Transaction costs paid directly by D-Wave Systems | — |  |  | (6,528) |
Proceeds from exercise of public warrants | — |  |  | 910 |
Proceeds from promissory note - related party | — |  |  | 420 |
Payment on directors and officers financing arrangement | (1,449) |  |  | (864) |
Proceeds from Lincoln Park Purchase Agreement | 61,346 |  |  | — |
Proceeds from issuance of common stock in connection with ESPP | 273 |  |  | — |
Proceeds from government assistance | 1,487 |  |  | 3,124 |
Proceeds from issuance of common stock upon exercise of stock options | 1,890 |  |  | 141 |
Proceeds from debt financing | 29,007 |  |  | 19,870 |
Debt payments | (390) |  |  | (20,000) |
Venture Loan interest and final payment fee | — |  |  | (1,808) |
Government loan payment | — |  |  | (398) |
Short swing profit settlement | 244 |  |  | — |
Net cash provided by financing activities | 92,408 |  |  | 38,967 |
Effect of exchange rate changes on cash and cash equivalents | (70) |  |  | (31) |
Net increase in cash and cash equivalents | 46,252 |  |  | 4,281 |
Cash and cash equivalents at beginning of period | 7,065 |  |  | 9,483 |
Cash and cash equivalents at end of period | $ | 53,317 |  |  | $ | 13,764 |
Supplemental disclosure of noncash investing and financial activities: |  |  |
Transfer from inventory to property and equipment | $ | 152 |  |  | $ | — |
Purchases of property and equipment included in accounts payable | 53 |  |  | — |
Non-cash directors and officers insurance | — |  |  | 2,893 |
Initial warrant liabilities recognized in connection with closing of the Merger | — |  |  | 8,101 |
Non-cash Merger financing | — |  |  | 5,713 |
Issuance of shares for payment of Lincoln Park Purchase Agreement commitment fee | — |  |  | 3,271 |
Conversion of convertible preferred stock to common stock | — |  |  | 189,871 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
12

Table of Contents
D-Wave Quantum Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Description of Business
D-Wave Quantum Inc. ("D-Wave" or the “Company”) was incorporated under the General Corporation Law of the State of Delaware on January 24, 2022. The Company was formed for the purpose of effecting a merger between DPCM Capital, Inc. (“DPCM”), D-Wave Systems Inc. (“D-Wave Systems”), and certain other affiliated entities through a series of transactions (the “Merger”) pursuant to the definitive agreement entered into on February 7, 2022 (the “Transaction Agreement”). On August 5, 2022, in conjunction with the Merger, DPCM and D-Wave Systems became wholly-owned subsidiaries of, and are operated by, the Company. Upon the completion of the Merger, the Company succeeded to all of the operations of its predecessor, D-Wave Systems.
D-Wave is a commercial quantum computing company that provides customers with a full suite of professional services and web-based access to its superconducting quantum computer systems and integrated software environment through its cloud service, Leap TM. Historically, the Company has developed its own annealing superconducting quantum computer and associated software, and its current generation quantum system is the Advantage TM system.
D-Wave has three operating facilities, which it leases, in North America. These facilities are located in Burnaby, British Columbia, Richmond, British Columbia, and Palo Alto, California.
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial reporting and with the instructions to Form 10-Q/A and Article 10 of Regulation S-X. Accordingly, the condensed consolidated balance sheet as of December 31, 2022, has been derived from the audited consolidated financial statements at that date, but certain notes or other information that are normally required by U.S. GAAP have been omitted if they substantially duplicate the disclosures contained in the Company's annual audited consolidated financial statements.
Certain information and footnote disclosure normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission ("SEC"). In the opinion of the Company, the unaudited financial information for the interim periods presented reflects all adjustments, which are normal and recurring, necessary for a fair presentation of the consolidated statement of operations and comprehensive loss, balance sheet, and cash flows. Interim results should not be regarded as indicative of results that may be expected for any other period or the entire year.
The interim condensed consolidated financial statements included herein have been prepared on the same basis as the audited annual consolidated financial statements and reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K/A as of and for the year ended December 31, 2022 filed with the SEC on March 15, 2024.
The condensed consolidated statement of operations and comprehensive loss for the three and nine month periods ended September 30, 2023 are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023 or thereafter. All references to September 30, 2023 and 2022 in the notes to condensed consolidated financial statements are unaudited.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements upon consolidation.
13

Table of Contents
Restatement of Previously Issued Condensed Consolidated Financial Statements
As described in Note 3 - Restatement of Previously Issued Condensed Consolidated Financial Statements, our condensed consolidated financial statements as of and for the three and nine month periods ended September 30, 2023 and 2022 are restated in this Quarterly Report on Form 10-Q (this “Amendment No.1”, this “Quarterly Report” or this “Form 10-Q/A”) to reflect the corrections related to the accounting treatment of certain government assistance arrangements in the form of conditionally repayable loans with below-market interest rates (the "Arrangements"). The restated condensed consolidated financial statements are indicated as “Restated” in the unaudited condensed consolidated financial statements and accompanying notes, as applicable. See Note 3 - Restatement of Previously Issued Condensed Consolidated Financial Statements for further discussion.
Liquidity and going concern
The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern. Since its inception, the Company has incurred net losses and negative cash flows from operations. As of September 30, 2023, the Company had an accumulated deficit of $467.0 million. For the three and nine months ended September 30, 2023, the Company incurred a net loss of $16.1 million and $66.7 million, respectively. For the three and nine months ended September 30, 2022, the Company incurred a net loss of $11.7 million and $35.9 million, respectively. For the nine month period ended September 30, 2023 and 2022, the Company had net cash outflows from operating activities of $45.9 million and $34.3 million, respectively. As of September 30, 2023, the Company had $53.3 million of cash and working capital (current assets less current liabilities) of $14.7 million. The Company expects to incur additional operating losses and negative cash flows from operating activities as it continues to expand its commercial operations and research and development programs.
On April 13, 2023, (the "Closing Date") the Company entered into the Term Loan and Security Agreement (the "Term Loan"), by and between the Co mpany and PSPIB Unitas Investments II Inc. ("PSPIB" or the "Lender"), a related party to the Company's largest shareholder. As further described in Note 8 - Loans Payable, net, the Term Loan provides for an aggregate principal amount of $50.0 million to be made available to the Company in three tranches, subject to certain terms and conditions as defined in the Term Loan, including a financial covenant that measures the Company's revenue against certain minimum percentages of budgeted revenue per quarter. The first two tranches of the Term Loan, each amounting to $15.0 million in principal, were advanced to D-Wave on April 14, 2023 and July 13, 2023, respectively. The Lender agreed to modify certain conditions to the funding of the second tranche of the Term Loan, including delaying the delivery of a board-approved operating budget and plan for the Company’s fiscal years 2023 through 2027 to August 31, 2023 (later extended to December 31, 2023); modifying the condition that, prior to the funding of the second tranche,the Company shall have nominated an additional director that is either an employee of PSPIB or an independent director selected from PSPIB nominees to require such appointment at a later time at PSPIB’s option; and modifying notice deadline requirements for the r egistration or filings of intellectual property. PSPIB has also agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the second and third fiscal quarters ended June 30, 2023 and September 30, 2023, respectively. The availability of the third tranche of $20.0 million is subject to the satisfaction of certain conditions, including the closing of a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, the intellectual property valuation report submitted as a condition precedent to the second tranche remaining satisfactory to the Lender and the board-approved operating budget for 2023 through 2027 to be submitted by December 31, 2023, being satisfactory to the Lender. The deadline to provide the operating budget was extended to December 31, 2023 from August 31, 2023 by the fourth amendment to the Term Loan dated October 6, 2023. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche or will be able to comply with the covenants of the Term Loan, or that PSPIB will agree to waive covenants under the Term Loan in the future.
14

Table of Contents
In conjunction with the Merger, the Company and D-Wave Systems entered into a purchase agreement with Lincoln Park on June 16, 2022 (the "Purchase Agreement" or the "Purchase Agreement") which provides D-Wave the sole right, but not the obligation, to direct Lincoln Park to buy specified dollar amounts up to $150 million of D-Wave's common stock, par value $0.0001 per share (the "Common Shares") through November 1, 2025. The Purchase Agreement may provide the Company and D-Wave with additional liquidity to fund the business, subject to the conditions set forth in the agreement, including volume limitations tied to periodic market prices, ownership limitations restricting Lincoln Park from owning more than 9.9% of the then total outstanding Common Shares and a floor price of $1.00 at or below which the Company may not sell to Lincoln Park any Common Shares. When the Company sells shares to Lincoln Park, Lincoln Park may resell all, some, or none of those Common Shares at any time or from time to time in its discretion. For the nine months ended September 30, 2023, the Company has received $61.3 million in proceeds through the issuance of 39,487,104 Common Shares to Lincoln Park under the Purchase Agreement. In order for the Company to issue Common Shares under the Purchase Agreement, the Company's share price must be above the floor price of $1.00 per share. There is no assurance that the floor price will not fall below $1.00 preventing the Company from being able to make sales to Lincoln Park in the future.
To the extent that sufficient capital is not obtained through the cash received in connection with the proceeds of the Term Loan or the issuance of Common Shares under the Purchase Agreement with Lincoln Park, management will be required to obtain additional capital through the issuance of debt and/or equity, or other arrangements. However, there can be no assurance that D-Wave will be able to raise additional capital when needed or under acceptable terms. The issuance of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to the currently outstanding common stock. Any future debt may contain covenants and limit D-Wave’s ability to pay dividends or make other distributions to stockholders. If D-Wave is unable to obtain additional financing, operations will be scaled back or discontinued.
The Company is not currently in compliance with, and may be unable to regain and/or maintain compliance with, certain continued listing standards of the New York Stock Exchange ("NYSE"). If the Company is unable to cure any event of noncompliance with any continued listing standard of the NYSE within the applicable timeframe and other parameters set forth by the NYSE, or if the Company fails to maintain compliance with certain continued listing standards that do not provide for a cure period, it will result in the delisting of the Company’s common stock from the NYSE, which could negatively impact the trading price, trading volume and liquidity of, and have other material adverse effects on, the Company’s common stock and its ability to raise capital.
In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Codification (“ASC”) Topic 205-40, “Basis of Presentation—Going Concern”, management has determined that the Company's liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material.
Use of estimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes as of the date of the condensed consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience.
The Company’s accounting estimates and assumptions may change over time in response to risks and uncertainties, including uncertainty in the current economic environment due to inflation, increased interest rates, Ukraine/Russia conflict, the Israel-Hamas War, and any evolutions thereof. The change could be material in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstances that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.
15

Table of Contents
Debt
The Company determined that it is eligible for the fair value option election in connection with the Term Loan. The Term Loan meets the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4 and does not meet the definition of any of the financial instruments found within ASC 825-10-15-5 that are not eligible for the fair value option. At the date of issuance, the fair value of the Term Loan is derived from the instrument’s implied discount rate at inception.
Changes in the fair value of the Term Loan, other than changes associated with the Company's own credit risk, are recorded as gains or losses in the Company’s condensed consolidated statements of operations and comprehensive loss in each reporting period. Changes in fair value attributable to the Company's own credit risk are recorded in other comprehensive income or loss in the Company's condensed consolidated statements of operations and comprehensive loss in each reporting period; there have been no such changes for the three and nine months ended September 30, 2023. Under the fair value option, debt issuance costs are recorded in other expense in the Company’s condensed consolidated statements of operations and comprehensive loss.
The Term Loan is subject to certain repayment and prepayment provisions which the Company has considered in their valuation analysis. The valuation analysis performed as of the issuance date on April 13, 2023 and September 30, 2023 did not consider any amendments to the Term Loan that occurred subsequent to September 30, 2023 (See Note 8). A Monte Carlo simulation model was utilized to forecast the probability of the issuance of Common Shares under the Purchase Agreement to determine the estimated proceeds to be paid to the Lender along with a mandatory prepayment premium of 10%. Additionally, the Company estimated the probability for an event of default in the valuation analysis which would result in a mandatory prepayment of the outstanding principal and accrued and unpaid interest. A binomial lattice model was utilized to determine the impact on the valuation of optional prepayments, in the event a mandatory prepayment does not occur. The Company assessed the fair value of the Term Loan at issuance date and as of September 30, 2023 resulting in unrealized gains of $1.7 million and $1.4 million for the three and nine months ended September 30, 2023, respectively.
Sales of future revenues - debt (As Restated)
On November 20, 2020, the Company entered into an agreement with the Canada Strategic Innovation Fund ("SIF"), wherein SIF committed to providing a conditionally repayable loan to the Company in the amount of up to C$40.0 million ("the SIF Loan"). The SIF Loan is conditionally repayable according to a revenue-based formula. See Note 8 for additional information concerning the SIF Loan.
The Company accounted for the SIF Loan using the "sale of future revenues" guidance outlined in ASC 470-10-25 and concluded that the arrangement should be treated as debt rather than deferred revenue. The debt arising from the SIF Loan was recorded at face value and will be amortized using the effective interest method, leading to the accrual of interest expenses over the estimated term of the SIF Loan. The amortization schedule is based on projected cash flows derived from the Company's long-term revenue forecast. Subsequent changes in forecasted cash flows will be accounted for under the catch-up method, which entails adjusting the accrued interest portion of the principal balance through earnings to reflect the effective interest rate. The liability is classified as non-current at September 30, 2023 and December 31, 2022, as the current forecast indicates that repayments will not commence within the 12 months following the balance sheet date.
As the SIF Loan is a government assistance arrangement in the form of a conditionally repayable loan with a below-market interest rate, a market rate of interest is not imputed in accordance with the scope limitations of ASC 835.
Fair value of financial instruments
Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1—Quoted prices in active markets for identical assets or liabilities.
•Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
16

Table of Contents
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.
The Company carries its marketable investments at cost, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments by the same issuer, as they represent investments in privately held companies for which there are no quoted market prices. As of September 30, 2023 and December 31, 2022, the carrying values of the Company's marketable investments were $1.2 million, respectively, and were reported in other noncurrent assets in the condensed consolidated balance sheets.
The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis as of September 30, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):

Description | Level |  | September 30, 2023
Liabilities: |  |  |
Warrant Liabilities – Public Warrants | 1 |  | $ | 1,091 |
Warrant Liabilities – Private Placement Warrants | 2 |  | $ | 880 |
Term Loan | 3 |  | $ | 29,800 |

The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the condensed consolidated statements of operations.
For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrants was used as the fair value of the Warrants as of each relevant date. The subsequent measurements of the Public Warrants after the detachment of the Public Warrants from the Units are classified as Level 1 fair value measurements due to the use of an observable market quote in an active market. The subsequent measurements of the Private Warrants after the detachment of the Public Warrants from the Units are classified as Level 2 fair value measurements due to the use of an observable market quote for the Public Warrants, which are considered to be a similar asset in an active market.
As of September 30, 2023, the liabilities for the Warrants were calculated by multiplying the quoted market price per DPCM Public Warrant of $0.11 by the 17,916,606 Warrants outstanding (see Note 9).
The Company elected the fair value option for its Term Loan. This liability is deemed to be a Level 3 valuation. The Company adjusts the Term Loan to fair value with adjustments recorded in change in fair value of Term Loan on the accompanying condensed consolidated statements of operations and comprehensive loss.
Government assistance
The Company receives various forms of government assistance including (i) government grants, (ii) investment credits and (iii) conditionally repayable loans with below-market interest rates (see Sales of future revenues - debt (As Restated) above).
During the three and nine months ended September 30, 2022, the Company recorded Scientific Research and Experimental Development (“SR&ED") investment tax credits of nil and $0.1 million, respectively, as an offset to its research and development expenses in its condensed consolidated statements of operations and comprehensive loss. Upon entering into the Transaction Agreement on February 7, 2022, the Company is no longer a Canadian Controlled Private Corporation. As a result, beginning February 7, 2022, SR&ED investment tax credits can be applied to reduce income taxes payable to the Canadian government and any such investment tax credits that are not realized will be reflected as investment tax credit carryforwards. During the three and nine months ended September 30, 2023, the Company did not record any SR&ED investment tax credits.
Recent accounting pronouncements issued and adopted
No recently issued accounting pronouncements that the Company has adopted have had a material effect on the Company's results of operations, cash flows or financial condition.
17

Table of Contents
Recent accounting pronouncements not yet adopted
No other recently issued accounting pronouncements or effective during 2023 had, or are expected to have, a material impact on the Company’s results of operations, cash flows or financial condition.
3. Restatement of Previously Issued Condensed Consolidated Financial Statements
On January 30, 2024, the Audit Committee of the Board of Directors of the Company, after discussions with the Company's management and its current and former independent registered public accounting firms, determined that the Company’s unaudited financial statements included in the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2023, filed with the SEC on November 9, 2023, as well as the relevant portions of any communication which describe or are based on the unaudited financial statements, should no longer be relied upon.
This Note discloses the nature of the restatement adjustments and discloses the cumulative effects of these adjustments on the condensed consolidated balance sheets, statements of operations, and statements of cash flows for the three and nine month periods ended September 30, 2023 and 2022 included in the original Form 10-Q. The condensed consolidated statements of stockholders’ (deficit) equity for the three and nine month periods ended September 30, 2023 and 2022 have also been restated for the correction to net loss.
Description of Restatement Adjustments
The restatement is related solely to the accounting treatment for certain government assistance arrangements with SIF and TPC that originated prior to 2021 in the form of conditionally repayable loans with below-market interest rates (the "Arrangements"). In connection with the preparation of the financial statements for fiscal year 2023, it was determined that the Arrangements were not properly accounted for. The Company initially accounted for these arrangements by analogizing to IAS 20 and IFRS 9, under which the fair value of the interest rate subsidy is recognized as income and the amount repayable is discounted by imputing a market rate of interest. During the preparation of the financial statements for fiscal year 2023, the Company determined that the debt-like characteristics of the Arrangements placed them in the scope of US GAAP guidance that precludes imputation of interest where interest rates are affected by tax attributes or legal restrictions prescribed by a governmental agency. As such, the Company restated other income from government assistance and interest expense on the condensed consolidated statements of operations and comprehensive loss and research incentives receivable and loans payable on the consolidated balance sheets to eliminate the effect of non-cash interest imputation. In addition to revenue projections, the revenue-based formula that determines the cash repayments under the SIF Loan requires other inputs, including the compound annual growth rate. An error related to the compound annual growth rate input in the estimation of debt repayment cash flows was also corrected.
The effects of the restatement, including the related income tax impacts are reflected in the impacted tables and footnotes throughout these consolidated financial statements in this Amendment No. 1. The restatement adjustments and their impacts on the previously issued condensed consolidated financial statements included in the original Form 10-Q are described below.
Condensed Consolidated Financial Statements - Restatement Reconciliation Tables
In light of the foregoing, in accordance with ASC 250, Accounting Changes and Error Corrections, we are restating the previously issued condensed consolidated financial statements for the three and nine month periods ended September 30, 2023 and 2022, to reflect the effects of the restatement adjustments, and to make certain corresponding disclosures. In the following tables, we have presented a reconciliation of our condensed consolidated balance sheets, statements of operations, and cash flows as previously reported for these prior periods to the restated and revised amounts. Financial statement line items and subtotals that were not impacted by the restatement adjustments have been omitted for enhanced clarity.
Summary of Restatement - Condensed Consolidated Balance Sheets

| As of September 30, 2023
(In thousands) | As Previously Reported |  | Restatement Adjustments |  | As Restated
Loans payable, net, current | $ | 30,006 |  |  | $ | 193 |  |  | $ | 30,199 |
Total current liabilities | 43,328 |  |  | 193 |  |  | 43,521 |
Loans payable, net, noncurrent | 9,108 |  |  | 23,722 |  |  | 32,830 |
Total liabilities | 61,383 |  |  | 23,915 |  |  | 85,298 |
Accumulated deficit | (443,132) |  |  | (23,915) |  |  | (467,047) |
Total stockholders' equity (deficit) | 8,796 |  |  | (23,915) |  |  | (15,119) |
Total liabilities and stockholders’ equity (deficit) | 70,179 |  |  | — |  |  | 70,179 |

18

Table of Contents
Summary of Restatement - Condensed Consolidated Statements of Operations

| Three Months Ended September 30,
| 2023 |  | 2022
(In thousands, except share and per share data) | As Previously Reported |  | Restatement Adjustments |  | As Restated |  | As Previously Reported |  | Restatement Adjustments |  | As Restated
Loss from operations | $ | (18,407) |  |  | $ | — |  |  | $ | (18,407) |  |  | $ | (15,164) |  |  | $ | — |  |  | $ | (15,164) |
Other income (expense), net: |  |  |  |  |  |  |  |  |  |  |
Interest expense | (1,247) |  |  | 212 |  |  | (1,035) |  |  | (1,069) |  |  | 436 |  |  | (633) |
Government assistance | 1,051 |  |  | (1,051) |  |  | — |  |  | — |  |  | — |  |  | — |
Other income (expense), net | 365 |  |  | 562 |  |  | 927 |  |  | 948 |  |  | 1,225 |  |  | 2,173 |
Total other income (expense), net | 2,578 |  |  | (277) |  |  | 2,301 |  |  | 1,853 |  |  | 1,661 |  |  | 3,514 |
Net loss | (15,829) |  |  | (277) |  |  | (16,106) |  |  | (13,311) |  |  | 1,661 |  |  | (11,650) |
Net loss per share, basic and diluted | (0.12) |  |  | — |  |  | (0.12) |  |  | (0.11) |  |  | 0.01 |  |  | (0.10) |
Weighted-average shares * used in computing net loss per share, basic and diluted | 133,222,318 |  |  | — |  |  | 133,222,318 |  |  | 116,256,805 |  |  | — |  |  | 116,256,805 |
Net comprehensive loss | (15,814) |  |  | (277) |  |  | (16,091) |  |  | (13,255) |  |  | 1,661 |  |  | (11,594) |

| Nine Months Ended September 30,
| 2023 |  | 2022
(In thousands, except share and per share data) | As Previously Reported |  | Restatement Adjustments |  | As Restated |  | As Previously Reported |  | Restatement Adjustments |  | As Restated
Loss from operations | $ | (64,004) |  |  | $ | — |  |  | $ | (64,004) |  |  | $ | (38,427) |  |  | $ | — |  |  | $ | (38,427) |
Other income (expense), net: |  |  |  |  |  |  |  |  |  |  |
Interest expense | (2,482) |  |  | 660 |  |  | (1,822) |  |  | (3,588) |  |  | 1,336 |  |  | (2,252) |
Government assistance | 1,051 |  |  | (1,051) |  |  | — |  |  | — |  |  | — |  |  | — |
Other income (expense), net | (59) |  |  | 25 |  |  | (34) |  |  | 1,301 |  |  | 1,481 |  |  | 2,782 |
Total other income (expense), net | (2,331) |  |  | (366) |  |  | (2,697) |  |  | (313) |  |  | 2,817 |  |  | 2,504 |
Net loss | (66,335) |  |  | (366) |  |  | (66,701) |  |  | (38,740) |  |  | 2,817 |  |  | (35,923) |
Net loss per share, basic and diluted | (0.50) |  |  | (0.01) |  |  | (0.51) |  |  | (0.32) |  |  | 0.03 |  |  | (0.29) |
Weighted-average shares * used in computing net loss per share, basic and diluted | 131,373,959 |  |  | — |  |  | 131,373,959 |  |  | 122,337,727 |  |  | — |  |  | 122,337,727 |
Net comprehensive loss | (66,405) |  |  | (366) |  |  | (66,771) |  |  | (38,722) |  |  | 2,817 |  |  | (35,905) |

19

Table of Contents
Summary of Restatement - Condensed Consolidated Statements of Cash Flows

| Nine Months Ended September 30,
| 2023 |  | 2022
(In thousands) | As Previously Reported |  | Restatement Adjustments |  | As Restated |  | As Previously Reported |  | Restatement Adjustments |  | As Restated
Net loss | $ | (66,335) |  |  | $ | (366) |  |  | $ | (66,701) |  |  | $ | (38,740) |  |  | $ | 2,817 |  |  | $ | (35,923) |
Adjustments to reconcile net loss to cash used in operating activities: |  |  |  |  |  |  |  |  |  |  |
Non-cash interest expense | 2,405 |  |  | (660) |  |  | 1,745 |  |  | $ | 1,616 |  |  | (1,336) |  |  | 280 |
Government assistance | (1,051) |  |  | 1,051 |  |  | — |  |  | $ | — |  |  | — |  |  | — |
Unrealized foreign exchange loss (gain) | (15) |  |  | (25) |  |  | (40) |  |  | $ | (1,226) |  |  | (1,481) |  |  | (2,707) |
Net cash used in operating activities | (45,910) |  |  | — |  |  | (45,910) |  |  | (34,339) |  |  | — |  |  | (34,339) |
Net cash used in investing activities | (176) |  |  | — |  |  | (176) |  |  | (316) |  |  | — |  |  | (316) |
Net cash provided by financing activities | 92,408 |  |  | — |  |  | 92,408 |  |  | 38,967 |  |  | — |  |  | 38,967 |
Effect of exchange rate changes on cash and cash equivalents | (70) |  |  | — |  |  | (70) |  |  | (31) |  |  | — |  |  | (31) |

4. Merger
On August 5, 2022, the Company completed the Merger. Upon the closing of the Merger, the following occurred:
•Each non-redeeming share of DPCM Class A common stock was converted into the right to receive 1.4541326 Common Shares (the “Exchange Ratio”), such that 902,213 shares of DPCM Class A common stock that were not redeemed were exchanged for 1,311,937 Common Shares;
•All outstanding warrants of DPCM were converted into the right to receive Warrants. Each such Warrant is exercisable for 1.4541326 Common Shares, at any time commencing on September 4, 2022, the date that is 30 days after the completion of the Merger. The number of Common Shares received upon the exercise of Warrants will be rounded down to the nearest whole number of Common Shares;
•3,015,575 shares of DPCM Class B common stock held by CDPM Sponsor Group LLC (the “Sponsor”) and DPCM’s officers, directors and other special advisors were converted into Common Shares on a one-for-one basis; and
•Pursuant to an arrangement effected under Part 9, Division 5 of the Business Corporations Act (British Columbia) (the “Arrangement”) all holders of outstanding non-redeemable convertible preferred shares of D-Wave Systems received equity interests in D-Wave in exchange for their equity interests in D-Wave Systems. The aggregate consideration paid to former shareholders of D-Wave Systems in connection with the Merger was approximately 99,736,752 Common Shares and Exchangeable Shares (as defined below) (excluding options of D-Wave Systems and warrants of D-Wave Systems).
“Exchangeable Shares” refers to shares in the capital of D-Wave Quantum Technologies Inc., or ExchangeCo, an indirect Canadian subsidiary of D-Wave. The Exchangeable Shares are exchangeable from time to time, at the holder’s election, for Common Shares on a one-for-one basis.
In connection with the Merger and concurrently with the execution of the Transaction Agreement, on February 7, 2022, DPCM and the Company entered into separate subscription agreements with a number of investors (each a "PIPE Investor"), pursuant to which the PIPE Investors agreed to purchase, and the Company agreed to sell to the PIPE Investors, a number of Common Shares (the “PIPE Shares”) equal to the aggregate purchase price for all Common Shares subscribed for by each PIPE Investor, divided by $10.00 and multiplied by the Exchange Ratio for an aggregate purchase price of $40.0 million (the “PIPE Investment”), such that the PIPE Investors purchased 5,816,528 PIPE Shares in the aggregate. The PIPE Investment closed simultaneously with the consummation of the Merger.
20

Table of Contents
On August 2, 2022, the DPCM shareholders voted to approve the Merger. Management determined that once this vote had occurred, it was probable that D-Wave Quantum Inc. would be required to pay Lincoln Park the Commitment Fee associated with the Purchase Agreement. As such, on August 2, 2022, D-Wave Quantum Inc. incurred a $2.6 million liability payable to Lincoln Park, which was the amount of cash contractually required to settle the Commitment Fee. Other than the Commitment Fee liability, D-Wave Quantum, Inc. had no other assets, liabilities, or operations prior to the closing of the Merger on August 5, 2022.
The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, DPCM was treated as the "acquired" company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of DPCM, accompanied by a recapitalization. The net assets of DPCM were stated at historical cost, with no goodwill or other intangible assets recorded.
5. Revenue from Contracts with Customers
Disaggregation of revenue
The following table depicts the disaggregation of revenue by type of products or services and timing of transfer of products or services (in thousands):

| Three months ended September 30,
| 2023 |  | 2022
Type of products or services |  |  |
QCaaS | $ | 1,132 |  |  | $ | 1,346 |
Professional services | 1,421 |  |  | 347 |
Other revenue | 9 |  |  | 2 |
Total revenue | $ | 2,562 |  |  | $ | 1,695 |
Timing of revenue recognition |  |  |
Revenue recognized over time | $ | 2,506 |  |  | $ | 1,660 |
Revenue recognized at a point in time | 56 |  |  | 35 |
Total revenue | $ | 2,562 |  |  | $ | 1,695 |

| Nine months ended September 30,
| 2023 |  | 2022
Type of products or services |  |  |
QCaaS | $ | 3,333 |  |  | $ | 3,905 |
Professional services | 2,482 |  |  | 812 |
Other revenue | 37 |  |  | 61 |
Total revenue | $ | 5,852 |  |  | $ | 4,778 |
Timing of revenue recognition |  |  |
Revenue recognized over time | $ | 5,713 |  |  | $ | 4,618 |
Revenue recognized at a point in time | 139 |  |  | 160 |
Total revenue | $ | 5,852 |  |  | $ | 4,778 |

Other revenue includes training and printed circuit board sales.
The following tables present a summary of revenue by geography, based on the addresses of our customers, for the three and nine months ended September 30, 2023 and 2022 (in thousands):
21

Table of Contents

| Three months ended September 30,
| 2023 |  | 2022
United States | $ | 1,083 |  |  | $ | 951 |
Japan | 299 |  |  | 293 |
Germany | 287 |  |  | 237 |
Switzerland | 311 |  |  | — |
Other | 582 |  |  | 214 |
Total revenue | $ | 2,562 |  |  | $ | 1,695 |

| Nine Months Ended September 30,
| 2023 |  | 2022
United States | $ | 1,814 |  |  | $ | 2,461 |
Japan | 920 |  |  | 1,008 |
Germany | 865 |  |  | 757 |
Switzerland | 686 |  |  | — |
Other | 1,567 |  |  | 552 |
Total revenue | $ | 5,852 |  |  | $ | 4,778 |

"Other" includes the rest of Europe, the Middle East, Africa, Asia, Canada and Australia where the revenue from a single country is not greater tha n 10% of total consolidated revenue. The Company has not had any sales in China, Russia or Ukraine.
Significant customers
The Company had significant customers during the three and nine months ended September 30, 2023 and 2022. A significant customer is defined as one that comprises up to ten percent or more of total revenues in a particular year or ten percent of outstanding accounts receivable balance as of the year end.
The tables below present the significant customers on a percentage of total revenue basis for the three and nine months ended September 30, 2023 and 2022.

| Three months ended September 30,
| 2023 |  | 2022
Customer A | 13 | % |  | 15 | %
Customer B | 9 | % |  | 11 | %
Customer C | — | % |  | 10 | %
Customer D | 12 | % |  | — | %
Customer E | 12 | % |  | — | %

| Nine Months Ended September 30,
| 2023 |  | 2022
Customer A | 2 | % |  | 13 | %
Customer B | 12 | % |  | 13 | %
Customer C | 12 | % |  | — | %

As of September 30, 2023 and December 31, 2022, there were three and two significant customers that comprised ten percent or more of outstanding accounts receivable balances, respectively.
All revenues derived from major customers above are located in the United States, Germany and other European countries during the three and nine month period ended September 30, 2023 and the United States and Germany during the three and nine month period ended September 30, 2022.
22

Table of Contents
Contract balances
The following table provides information about account receivable, contract assets and liabilities as of September 30, 2023 and December 31, 2022 (in thousands):

| September 30, |  | December 31,
| 2023 |  | 2022
Contract assets: |  |  |
Trade accounts receivable, excluding unbilled receivables | $ | 395 |  |  | $ | 757 |
Unbilled receivables 1 | 368 |  |  | 58 |
Total contract assets | $ | 763 |  |  | $ | 815 |
Contract liabilities: |  |  |
Deferred revenue, current | $ | 2,177 |  |  | $ | 1,781 |
Deferred revenue, noncurrent | 92 |  |  | 9 |
Customer deposit 2 | 45 |  |  | 45 |
Total contract liabilities | $ | 2,314 |  |  | $ | 1,835 |

1 As of December 31, 2022, there was an immaterial amount of unbilled receivables classified as prepaid expenses and other current assets on the condensed consolidated balance sheets.
2 Customer deposit is included in "Accrued expenses and other current liabilities" on the condensed consolidated balance sheets.
The allowance for doubtful accounts balance was nil as of September 30, 2023 and December 31, 2022, respectively.
Changes in deferred revenue from contracts with customers were as follows (in thousands):

|  |  | Nine months ended September 30, 2023
Balance at beginning of period |  |  | $ | 1,790 |
Deferral of revenue |  |  | 4,353 |
Recognition of deferred revenue |  |  | (3,874) |
Balance at end of period |  |  | $ | 2,269 |

Total deferred revenue as of December 31, 2022 was $1.8 million, of which $1.7 million was recognized as revenues during the nine months ended September 30, 2023.
Remaining performance obligations
A significant number of the Company’s product and service sales are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.
As of September 30, 2023, the aggregate amount of remaining performance obligations that were unsatisfied or partially unsatisfied related to customer contracts was $4.4 million. This amount included deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 84% is expected to be recognized to revenue in the next 12 months.
23

Table of Contents
6. Balance Sheet Details
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):

| September 30, |  | December 31,
| 2023 |  | 2022
Accrued expenses: |  |  |
Accrued transaction costs | $ | — |  |  | $ | 2,459 |
Accrued professional services | 2,642 |  |  | 1,858 |
Accrued compensation and related benefits | 3,707 |  |  | 1,641 |
Other accruals | 993 |  |  | 233 |
Other current liabilities: |  |  |
Other payroll expenses | 722 |  |  | 451 |
Customer deposit | 45 |  |  | 45 |
Current portion of operating lease liabilities | 1,390 |  |  | 1,533 |
Promissory note, related party (Refer to Note 10 - Promissory note, related party) | 105 |  |  | 420 |
Total accrued expenses and other current liabilities | $ | 9,604 |  |  | $ | 8,640 |

Prepaid expenses and other current assets consisted of the following (in thousands):

| September 30, |  | December 31,
| 2023 |  | 2022
Prepaid expenses: |  |  |
Prepaid services | $ | 377 |  |  | $ | 391 |
Prepaid software | 563 |  |  | 559 |
Prepaid rent | 182 |  |  | 96 |
Prepaid commissions | 87 |  |  | 268 |
Prepaid insurance | 338 |  |  | 697 |
Other | 142 |  |  | 89 |
Other current assets: |  |  |
Receivable research incentives | 128 |  |  | 264 |
Security deposits | 17 |  |  | 36 |
Directors and officers insurance | 36 |  |  | 1,449 |
Unbilled receivables | — |  |  | 58 |
Total prepaid expenses and other current assets | $ | 1,870 |  |  | $ | 3,907 |

24

Table of Contents
7. Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):

| September 30, |  | December 31,
| 2023 |  | 2022
Quantum computer systems | $ | 13,711 |  |  | $ | 13,714 |
Lab equipment | 6,838 |  |  | 6,666 |
Computer equipment | 3,614 |  |  | 3,545 |
Leasehold improvements | 1,075 |  |  | 1,075 |
Furniture and fixtures | 372 |  |  | 319 |
Construction-in-progress | 119 |  |  | 86 |
Total property and equipment | 25,729 |  |  | 25,405 |
Less: Accumulated depreciation | (23,850) |  |  | (23,111) |
Total Property and equipment, net | $ | 1,879 |  |  | $ | 2,294 |

Depreciation expense for the three month period ended September 30, 2023 and 2022 was $0.2 million and $0.3 million, respectively. Depreciation expense for the nine month period ended September 30, 2023 and 2022 was $0.7 million and $1.0 million, respectively. The Company has not acquired any property and equipment under capital leases.
As of September 30, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets, consisting of property and plant, net, and operating lease right-of-use assets, amount ing to $10.4 million and $11.4 million, respectively, are located in North America, principally in Canada.
8. Loans Payable, net (As Restated)
As of September 30, 2023 and December 31, 2022 loans payable consisted of the refundable government loans. The following table shows the component of loans payable (in thousands):

| Interest Rate |  | September 30, |  | December 31,
|  | 2023 |  | 2022
Loans payable, current: |  |  | (As Restated) |  | (As Restated)
Term Loan 1 | 11.00% |  | $ | 29,800 |  |  | $ | — |
TPC Loan, due 2024 | Interest free |  | 399 |  |  | 399 |
Financing of directors and officers insurance, due 2023 | 4.24% |  | — |  |  | 1,449 |
Other loans payable, current, due 2023 |  |  | — |  |  | 15 |
Total loans payable, current |  |  | $ | 30,199 |  |  | $ | 1,863 |
Loans payable, noncurrent: |  |  |  |  |
SIF Loan 1 |  |  | $ | 32,462 |  |  | $ | 30,434 |
TPC Loan, due 2025 | Interest free |  | 368 |  |  | 734 |
Total loans payable, noncurrent |  |  | $ | 32,830 |  |  | $ | 31,168 |

1 Refer below for additional information on the repayment period and effective interest rate.
SIF Loan
On November 20, 2020, the Company entered into an agreement with SIF, wherein SIF committed to providing a conditionally repayable loan to the Company in the amount of up to C$40.0 million. As of September 30, 2023, the Company has received C$38,000,000 in funding from SIF. Funds from the SIF Loan are to be used for projects involving the adaptation of research findings for commercial applications that have the potential for market disruption; development of current product and services through the implementation of new or incremental technology that will enhance the Company’s competitive capability; and development of process improvements which reduce the environmental footprint of current production through the use of new or improved technologies.
25

Table of Contents
Principal and interest amounts to be repaid under the SIF Loan are determined using a revenue-based formula, and are capped at 150% of the principal amount (the "Repayment Cap"). Repayments are due in up to 15 annual installments, commencing on April 30 of the second fiscal year following the fiscal year in which the Company first reports annual revenue of at least $70.0 million (the "Benchmark Year"). If the Company fails to reach $70.0 million in annual revenue after 14 years from origination, or if the total of the 15 revenue-based annual installments is less than the principal amount, any remaining repayment obligation will be forgiven.
Repayments of the SIF Loan can also be triggered upon default of the agreement, termination of the agreement, or upon a change of control that has not been approved by the Canadian government. The Canadian government conditionally approved the transaction with DPCM on May 9, 2022, with all conditions met on the closing date of the Merger. As of September 30, 2023, the Company is not aware of events that would trigger default or termination of the agreement.
The gross proceeds of the SIF Loan were recorded as a liability related to the sale of future revenues (see Note 2 - Basis of Presentation and Summary of Significant Accounting Policies). As of September 30, 2023 and 2022, the Company calculated a weighted average effective interest rate for all tranches of 2.50% and 2.36%, respectively, based on the most recent revenue projections at each reporting date.
Term Loan
On April 13, 2023, the Company entered into the Term Loan with PSPIB. Under the Term Loan, term loans in aggregate principal amount of $50.0 million are to be made available to the Company in three tranches, subject to certain terms and conditions.
The Term Loan matures on March 31, 2027, is secured by a first-priority security interest in substantially all of the Company's assets and contains certain operational and financial covenants, including a financial covenant that measures the Company's revenue against certain minimum percentages of budgeted revenue per quarter. The Term Loan is subject to a 2% drawdown fee and requires that any proceeds from the issuance of Common Shares under the Purchase Agreement be applied towards the repayment of advances under the Term Loan. Such repayments are subject to a premium payment equal to 10.0% of the amount then prepaid to the Lender, in addition to the regular prepayment premium applicable on that date, except as modified by the amendment to the Term Loan as discussed below. The Term Loan is subject to a prepayment premium due to the Lender equal to 3% of the amount prepaid/repaid within the first year of the Closing Date, 2% in the second year, 1% in the third year and no prepayment premium thereafter. At the Company's discretion, the Term Loan bears interest on a monthly basis at either (i) 10.0% payable in cash, or (ii) 11.0% payable in kind ('PIK'), with the latter added to the principal value of the Term Loan. For the three and nine months ended September 30, 2023 the Company recognized $0.8 million and $1.2 million in PIK interest expense related to the Term Loan, respectively.
Prior to PSPIB's advance of the first tranche, the Company satisfied several closing conditions including the provision of a cash flow forecast and the board of directors' retention of an advisor. The first and second tranche of the Term Loan, each in an aggregate principal amount of $15.0 million, were advanced to D-Wave on April 14, 2023 and July 13, 2023, with the third tranche of $20.0 million to be made automatically available to the Company subject to the satisfaction of certain conditions. For the three and nine months ended September 30, 2023, the Company has recorded debt issuance cost of $2.1 million as other expense in its condensed consolidated statements of operations and comprehensive loss. PSPIB has agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the fiscal quarters ended June 30, 2023 and September 30, 2023. As a result of not meeting the minimum revenue covenant, as of September 30, 2023 the Company assessed its ability to meet such covenant over the next 12 months in accordance with ASC Topic 470, "Debt" and determined that the Term Loan may be callable over this period. T herefore the Term Loan was classified as a current liability on the Company's consolidated balance sheets as of September 30, 2023. There can be no assurance that PSPIB will agree to waive the minimum revenue or other covenants under the Term Loan in the future.
The availability of the third tranche is subject to the Company closing a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, the intellectual property valuation report submitted as a condition precedent to the second tranche remaining satisfactory to the Lender and providing a board-approved operating budget for 2023 through 2027 by August 31, 2023 that is satisfactory to the Lender. The deadline to provide the operating budget was extended to December 31, 2023 from August 31, 2023 by the fourth amendment to the Term Loan dated October 6, 2023. There can be no assurance that the Company will be able to meet the conditions necessary to draw on the third tranche.
26

Table of Contents
The Term Loan was amended such that the Company may issue up to $50.0 million under the Lincoln Park Purchase Agreement without the requirement to pay down the Term Loan to the extent that the proceeds under the Purchase Agreement are received prior to December 31 , 2023. As amended, the Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement in excess of $50.0 million shall be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10% of the amount then prepaid to the Lender.
9. Warrant Liabilities
Public and Private Warrants
In conjunction with the Merger, the Company assumed 10,000,000 DPCM public warrants and 8,000,000 DPCM private warrants. During the nine months ended September 30, 2023, no DPCM public or private warrants were exercised.
As of September 30, 2023, the Company has 17,916,606 Warrants outstanding. As part of the Merger, as described in Note 4 - Merger, each DPCM Public Warrant and Private Warrant that was issued and outstanding immediately prior to the Merger was automatically and irrevocably converted into one D-Wave Quantum warrant. The Warrants are subject to the terms and conditions of the warrant agreement entered into between DPCM, Continental Stock Transfer & Trust Company and the Company (the “Warrant Agreement Amendment” as specified in the Transaction Agreement).
Each such Warrant will be exercisable at an exercise price of $11.50 for 1.4541326 Common Shares, or an approximate exercise price per Common Share of $7.91, subject to adjustments. The Warrants may be exercised for a w hole number of shares of the Company. No fractional shares will be issued upon exercise of the Warrants. The Warrants will expire on August 5, 2027, or earlier upon redemption or liquidation.
The Private Warrants are identical to the Public Warrants except that the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
The Company may redeem the Public Warrants:
• in whole and not in part;
• at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the Common Share;
• if, and only if, the last reported sales price of the shares of the Common Shares for any twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which a notice of redemption is given equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalization and the like) (the "Reference Value");
• if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalization and the like), the Private Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above; and
• if, and only if, there is an effective registration statement covering the issuance of the Common Shares issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given, or an exemption from registration is available.
27

Table of Contents
If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the Warrant Agreement Amendment. The exercise price and number of the Common Shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of the Common Shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.
D-Wave Systems Warrant Transaction Agreements
In November 2020, contemporaneously with a revenue arrangement, D-Wave Systems entered into a contract pursuant to which D-Wave Systems agreed to cancel a previously issued warrant with a customer and replace it with a warrant to acquire up to 3,247,637 shares of its Class A Preferred Shares (the “Warrant Preferred Shares”), subject to certain vesting requirements. The warrant agreement was amended on August 5, 2022, contemporaneously with the closing of the Merger, to convert the Warrant Preferred Shares to a warrant to acquire up to 2,889,282 Common Shares of the Company in accordance with the Conversion Ratio (as defined below). The agreement was terminated November 28, 2022 and as a result, any unvested Warrant Preferred Shares will not vest and become exercisable. As of the termination date of November 28, 2022, approximately 40% of the warrants to acquire up to 2,889,282 Common Shares had vested, resulting in 1,155,713 Common Shares available to be issued after the termination date. The vested warrants will remain exercisable for up to 1,155,713 Common Shares at an exercise price of $2.16 per Common Share until November 29, 2026.
10. Related Party
Promissory notes
In 2022, DPCM and one of its affiliates entered into two unsecured promissory notes of up to $1.0 million each with the Sponsor (the "DPCM Notes"). The purpose of the DPCM Notes was to provide DPCM with additional working capital. All amounts drawn on the DPCM Notes were provided directly to DPCM. The DPCM Notes are not convertible and bear no interest. The principal balance of the DPCM Notes was originally due and payable upon the earlier of the date on which DPCM consummates its initial business combination, or the date that the winding up of DPCM is effective. A total of $0.4 million has been drawn on the DPCM Notes, of which $0.1 million remains outstanding as of September 30, 2023.
In connection with the Merger, the DPCM Notes were assumed by the Company and were amended and restated effective December 31, 2022. The amended and restated notes have identical terms as the DPCM Notes except that the Company must pay the principal balance in equal installments on December 31, 2022, March 31, 2023, and June 30, 2023.
In February 2023, these DPCM Notes were further amended and restated such that the Company must pay the principal balance in four equal installments on each of April 30, 2023, June 30, 2023, August 31, 2023, and October 31, 2023. Only the installment due on October 31, 2023 remains unpaid as of September 30, 2023.
The execution of the amended and restated DPCM Notes are related party transactions as these notes are payable to affiliates of the Company.
Short swing profit settlement
For the nine months ended September 30, 2023, the Company recorded approximately $0.2 million related to the short swing profit settlement remitted by a shareholder of the Company under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized the proceeds as an increase to additional paid-in-capital in the condensed consolidated balance sheets as of September 30, 2023, and in the condensed consolidated statements of stockholder's (deficit) equity, as well as in cash provided by financial activities in the condensed consolidated statement of cash flows, for the nine months ended September 30, 2023.
11. Stock-based Compensation
For the nine months ended September 30, 2023 and 2022, stock-based compensation is associated with stock options, restricted stock units ("RSUs"), and the Company's Employee Stock Purchase Plan ("ESPP").
28

Table of Contents
Common stock option activity
The following table summarizes the Company’s stock option activity during the periods presented (in thousands except share and per share data):

| Number of options outstanding | Weighted average exercise price ($) | Weighted average remaining contractual term (years) | Aggregate intrinsic value ($)
Balance as of December 31, 2022 | 15,387,546 | $ | 1.76 |  | 7.12 | $ | 8,763 |
Granted | — | — |  | — |  | — |
Exercised | (2,329,067) | 0.81 |  | — |  | 144 |
Forfeited | (1,019,743) | 3.57 |  | — |  | — |
Expired | (388,956) | 2.36 |  | — |  | — |
Balance as of September 30, 2023 | 11,649,780 | $ | 1.66 |  | 7.32 | $ | 1,618 |
Options exercisable as of September 30, 2023 | 9,809,565 | $ | 1.24 |  | 7.13 | $ | 1,438 |
Options unvested as of September 30, 2023 | 1,840,072 | $ | 3.89 |  | 8.35 | $ | 180 |

As of September 30, 2023, out of the total 11,649,780 options that have been issued and are currently outstanding, 10,587,799 options were originally granted under the 2020 Equity Incentive Plan (the "2020 Plan"). These options will be converted applying the conversion ratio of 0.889657 (the "Conversion Ratio") into 9,419,509 Common Shares upon exercise.
The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the estimated fair value of the Common Shares for those stock options that had exercise prices lower than the fair value of the Common Shares.
As of September 30, 2023, total unrecognized compensation cost related to unvested stock option grants was approximately $5.6 million. This amount is expected to be recognized over a weighted average period of approximately 0.81 years.
The total fair values of the stock options vested during the nine months ended September 30, 2023 and 2022 was $3.1 million and $3.1 million respectively.
Restricted stock unit awards
RSUs granted to employees under D-Wave's 2022 Equity Incentive Plan (the "2022 Plan") generally vest 25% on the first anniversary of the grant date, and then 6.25% each quarter subsequent to the first anniversary for twelve quarters. RSUs granted to members of the Board of Directors are subject to a service condition, and generally will be fully vested on the date of the Company's 2024 annual shareholder meeting.
The following table summarizes the RSU activity and related information under the 2022 Plan:

| Number of Outstanding |  | Weighted average Grant Date Fair Value ($)
Unvested as of December 31, 2022 | 8,143,304 |  |  | $ | 5.69 |
Granted | 4,423,933 |  |  | 0.89 |
Forfeited | (1,446,883) |  |  | 4.63 |
Vested | (167,605) |  |  | 4.02 |
Unvested as of September 30, 2023 | 10,952,749 |  |  | $ | 3.93 |
Expected to vest as of September 30, 2023 | 10,436,290 |  |  | $ | 3.97 |

As of September 30, 2023, the unrecognized stock-based compensation cost related to the RSUs was $24.3 million, which is expected to be recognized over a weighted-average period of 2.38 years.
Employee Stock Purchase Plan
In August 2022, the Company established the 2022 Employee Stock Purchase Plan (the "ESPP"). During the nine months ended September 30, 2023, 226,453 shares of common stock were issued under the ESPP.
29

Table of Contents
Stock-based compensation expense
The following table summarizes the stock-based compensation expense classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

| Three months ended September 30,
| 2023 |  | 2022
Cost of revenue | $ | 353 |  |  | $ | 45 |
Research and development | 2,347 |  |  | 360 |
General and administrative | 2,913 |  |  | 644 |
Sales and marketing | 271 |  |  | 732 |
Total stock-based compensation | $ | 5,884 |  |  | $ | 1,781 |

| Nine months ended September 30,
| 2023 |  | 2022
Cost of revenue | $ | 963 |  |  | $ | 80 |
Research and development | 6,771 |  |  | 536 |
General and administrative | 8,849 |  |  | 1,948 |
Sales and marketing | 779 |  |  | 791 |
Total stock-based compensation | $ | 17,362 |  |  | $ | 3,355 |

12. Commitments and Contingencies
Leases
The Company primarily enters into leases for office space that are classified as operating leases. During each of the nine months ended September 30, 2023, and 2022, total operating lease costs were $1.1 million.
Litigation
From time to time, the Company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.
In the normal course of business, the Company may agree to indemnify third parties with whom it enters into contractual relationships, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Company’s products when used for their intended purposes infringe the intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each particular claim.
As of September 30, 2023 and 2022, the Company was not subject to any material litigation or pending litigation claims.
30

Table of Contents
13. Net Loss per Share
As a result of the Merger (see Note 4), for the three months ended September 30, 2022, the Company has retroactively adjusted the weighted average shares outstanding prior to August 5, 2022 to give effect to the Conversion Ratio used to determine the number of Common Shares into which they were converted.
The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share data):

| For the three months ended September 30,
| 2023 |  | 2022
| (As Restated) |  | (As Restated)
Numerator: |  |  |
Net loss attributable to common stockholders - basic and diluted | $ | (16,106) |  |  | $ | (11,650) |
Denominator: |  |  |
Weighted-average common stock outstanding | 133,222,318 |  |  | 116,256,805 |
Net loss per share attributable to common stockholders - basic and diluted | $ | (0.12) |  |  | $ | (0.10) |

| For the nine months ended September 30,
| 2023 |  | 2022
| (As Restated) |  | (As Restated)
Numerator: |  |  |
Net loss attributable to common stockholders - basic and diluted | $ | (66,701) |  |  | $ | (35,923) |
Denominator: |  |  |
Weighted-average common stock outstanding | 131,373,959 |  |  | 122,337,727 |
Net loss per share attributable to common stockholders - basic and diluted | $ | (0.51) |  |  | $ | (0.29) |

As of September 30, 2023 and 2022, the Company’s potentially dilutive securities were stock options, the Warrant Shares, and the Public Warrants and Private Warrants.
Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.
Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

| As of September 30,
| 2023 |  | 2022
Public Warrants as converted to Common Shares (Note 9) | 14,420,064 |  |  | 14,426,301 |
Private Warrants as converted to Common Shares (Note 9) | 11,633,061 |  |  | 11,633,060 |
D-Wave Systems Warrant Shares as converted to Common Shares (Note 9) | 1,155,713 |  |  | 2,889,282 |
Options to purchase common stock as converted to Common Shares 1 | 9,419,509 |  |  | 13,532,543 |
Options to purchase Common Shares under the 2022 Equity Incentive Plan | 1,061,981 |  |  | 1,500,081 |
Unvested restricted stock unit awards | 10,952,749 |  |  | — |
Total | 48,643,077 |  |  | 43,981,267 |

1 Stock options granted under the 2020 Plan will be converted applying the Conversion Ratio to the underlying common stock at the exercise date.
14. Subsequent Events
The Company has evaluated subsequent events through the filing of this Report, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the condensed consolidated financial statements, except for the following:
31

Table of Contents
On October 20, 2023, the Company was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s common stock from the NYSE. On October 24, 2023, the Company notified the NYSE that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. The Company can regain compliance at any time within the six-month period following receipt of the NYSE notice if on the last trading day of any calendar month during the cure period the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE’s rules, if the Company determines that, if necessary, it will cure the stock price deficiency by taking an action that will require stockholder approval, it must so inform the NYSE in the above referenced notification and the price condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days. The Company intends to consider available alternatives, including but not limited to a reverse stock split, that are subject to shareholder approval. The Company’s common stock will continue to be listed and trade on the NYSE during this period, subject to the Company’s compliance with other NYSE continued listing standards.
32

Table of Contents
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion is intended to assist you in understanding our present business and the results of operations together with our present financial condition. This section should be read in conjunction with our unaudited condensed consolidated financial statements and the accompanying notes contained in Part I, Item I of this Report, as well as our Annual Report on Form 10-K/A for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 15, 2024. In this section, unless otherwise specified, the terms “we”, “our”, “us”, D-Wave" or the "Company" refer to D-Wave Quantum Inc. and its subsidiaries following the closing of the Merger on August 5, 2022 (the "Closing") while "D-Wave Systems" refers to D-Wave Systems Inc. prior to the Closing. All other capitalized terms have the meanings ascribed thereto elsewhere in this Report. All dollar amounts are expressed in thousands of United States dollars (“$”), unless otherwise indicated.
Restatement of Previously Issued Condensed Consolidated Financial Statements
In this Quarterly Report on Form 10-Q/A, we have restated our previously issued unaudited Financial Statements, Refer to the “Explanatory Note” preceding “Cautionary Note Regarding Forward-Looking Statements” for background on the restatement, the fiscal periods impacted and other information. As a result, we have also restated certain previously reported financial information for the three and nine month periods ended September 30, 2023 and 2022 in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including but not limited to information within the “Results of Operations” and “Liquidity and Capital Resources” sections to conform the discussion with the appropriate restated amounts. See “Item 1. Financial Statements and Supplementary Data-Notes to Condensed Consolidated Financial Statements-Note 3 - Restatement of Previously Issued Condensed Consolidated Financial Statements,” for additional information related to the Restatement.
Overview
We are a commercial quantum computing company that provides customers with a full suite of professional services and web-based access to our superconducting quantum computer systems and integrated software environment through our cloud service, Leap TM. Historically, we have developed our own annealing superconducting quantum computer and associated software, and our current generation quantum system is the Advantage TM system. We are a leader in the development and delivery of quantum computing systems, software and services, and we are the world’s first commercial supplier of quantum computers. Our business model is focused primarily on generating revenue from providing customers access to our quantum computing systems via the cloud in the form of Quantum Computing as a Service ("QCaaS") products, and from providing professional services wherein we assist our customers in identifying and implementing quantum computing applications.
During the three months ended September 30, 2023 and 2022, we recognized revenue from our cloud and professional services of $2.6 million and $1.7 million, respectively. We have incurred significant operating losses since inception. For the nine months ended September 30, 2023 and 2022, our net loss w as $66.7 million and $35.9 million, respectively. We expect to continue to incur significant losses for the foreseeable future as we continue to invest in various research and development programs and go-to-market initiatives. As of September 30, 2023, we had an accumulated deficit of $467.0 million.
Macroeconomic Environment
Unfavorable conditions in the economy in the United States, Canada and abroad, including conditions resulting from changes in gross domestic product growth, labor shortages, supply chain disruptions, inflationary pressures, rising interest rates, financial and credit market fluctuations, banking collapses and related uncertainty, international trade relations, political turmoil, natural catastrophes, outbreaks of contagious diseases, warfare and terrorist attacks on the United States, Europe or elsewhere, including military actions affecting Russia, Ukraine, Israel, Palestine or elsewhere, could cause a decrease in business investments on our products and negatively affect the growth of our business and our results of operations.
33

Table of Contents
Key Components of Results of Operations
Revenue
We primarily generate our revenue through subscription sales to access our QCaaS cloud platform and professional services that assist our customers in identifying and implementing applications that leverage our QCaaS cloud platform. QCaaS revenue is recognized on a ratable basis over the contract term, which generally ranges from one month to two years. Professional services revenue is primarily recognized based on a percentage of completion basis as services are being delivered.
We expect that there will be a decrease in our cloud based recurring QCaaS revenue as a percentage of total revenue in 2023 when compared to 2022 due to increased demand for professional services engagements. In subsequent periods, we expect that the general trend will be for QCaaS revenue as a percentage of total revenue to increase due to an increasing number of QCaaS agreements being driven by the completion of professional services engagements yielding production applications that require QCaaS services, as well as by customers that choose to access our Leap cloud service without utilizing our professional services organization.
Cost of Revenue
Our cost of revenue consists of expenses related to providing our QCaaS offering and delivering our professional services, specifically personnel-related expenses, including stock-based compensation, and costs associated with maintaining the cloud platform on which the QCaaS resides. The cost of revenue also includes depreciation and amortization related to our quantum computing systems and related software.
We expect our total cost of revenue to increase in absolute dollars in future periods, corresponding to our anticipated growth in professional services revenue and related headcount as well to support our customers and to maintain the QCaaS cloud offering. Because the costs of delivering our QCaaS cloud offering are less than the costs for our professional services, we anticipate that an increase of QCaaS revenue will increase our gross margin in the longer term.
Operating Expenses
Our operating expenses consist of research and development, general and administrative, and sales and marketing expenses.
Research and Development
Research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel, fabrication costs, consulting and engineering services, lab supplies, and cloud computing resources and allocated facility costs for our research and development functions. Unlike a standard computer, design and development efforts continue throughout the useful life of our quantum computing systems to ensure proper calibration and optimal functionality. Research and development expenses also include purchased hardware components, fabrication and software costs related to quantum computing systems constructed for research purposes that do not have a high probability of providing near-term future economic benefits, and may have no alternate future use. We currently do not capitalize any research and development expenses. We expect to continue to make substantial investments in our research and development capabilities.
General and Administrative
General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel and outside professional services expenses including legal, audit and accounting services, insurance, other administrative expenses and allocated facility costs for our administrative functions. We expect to continue to invest in our general and administrative components, in particular in comprehensive compliance and governance functions, increased IT security and compliance, and enhanced internal controls over financial reporting.
Sales and Marketing
Sales and marketing expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation for personnel, direct advertising, marketing and promotional material costs, sales commission expense, consulting fees and allocated facility costs for our sales and marketing functions. We intend to continue to make significant investments in our sales and marketing organization to drive additional revenue, expand our global customer base, and broaden our brand awareness. We generally expect our sales and marketing expenses to continue to increase in absolute dollars for the foreseeable future as we invest in various go-to-market initiatives.
34

Table of Contents
Other income (expense), net
Other income (expense), net is primarily comprised of change in fair value of warrant liabilities and debt, debt issuance costs, interest expense and foreign currency gains or losses.
Results of Operations
The following table sets forth our results of operations for the periods indicated:

| Three Months Ended September 30,
| 2023 |  | 2022
(In thousands, except share and per share data) | (As Restated) |  | (As Restated)
Revenue | $ | 2,562 |  |  | $ | 1,695 |
Cost of revenue | 1,033 |  |  | 654 |
Total gross profit | 1,529 |  |  | 1,041 |
Operating expenses: |  |  |
Research and development | 9,459 |  |  | 7,507 |
General and administrative | 8,003 |  |  | 5,925 |
Sales and marketing | 2,474 |  |  | 2,773 |
Total operating expenses | 19,936 |  |  | 16,205 |
Loss from operations | (18,407) |  |  | (15,164) |
Other income (expense), net: |  |  |
Interest expense | (1,035) |  |  | (633) |
Change in fair value of warrant liabilities | 1,433 |  |  | 2,603 |
Government assistance | — |  |  | — |
Change in fair value of Term Loan | 1,701 |  |  | — |
Term Loan debt issuance costs | (725) |  |  | — |
Lincoln Park Purchase Agreement issuance costs | — |  |  | (629) |
Other income (expense), net | 927 |  |  | 2,173 |
Total other income (expense), net | 2,301 |  |  | 3,514 |
Net loss | $ | (16,106) |  |  | $ | (11,650) |
Foreign currency translation adjustment, net of tax | 15 |  |  | 56 |
Comprehensive loss | $ | (16,091) |  |  | $ | (11,594) |

35

Table of Contents

| Nine Months Ended September 30,
| 2023 |  | 2022
(In thousands, except share and per share data) | (As Restated) |  | (As Restated)
Revenue | $ | 5,852 |  |  | $ | 4,778 |
Cost of revenue | 3,197 |  |  | 1,858 |
Total gross profit | 2,655 |  |  | 2,920 |
Operating expenses: |  |  |
Research and development | 29,922 |  |  | 21,799 |
General and administrative | 28,875 |  |  | 13,566 |
Sales and marketing | 7,862 |  |  | 5,982 |
Total operating expenses | 66,659 |  |  | 41,347 |
Loss from operations | (64,004) |  |  | (38,427) |
Other income (expense), net: |  |  |
Interest expense | (1,822) |  |  | (2,252) |
Change in fair value of warrant liabilities | (79) |  |  | 2,603 |
Government assistance | — |  |  | — |
Change in fair value of Term Loan | 1,356 |  |  | — |
Term Loan debt issuance costs | (2,118) |  |  | — |
Lincoln Park Purchase Agreement issuance costs | — |  |  | (629) |
Other income (expense), net | (34) |  |  | 2,782 |
Total other income (expense), net | (2,697) |  |  | 2,504 |
Net loss | $ | (66,701) |  |  | $ | (35,923) |
Foreign currency translation adjustment, net of tax | (70) |  |  | 18 |
Comprehensive loss | $ | (66,771) |  |  | $ | (35,905) |

Comparison of the Three Months Ended September 30, 2023 and 2022
Revenue
Revenue increased $0.9 million, or 51%, to $2.6 million for the three months ended September 30, 2023 as compared to $1.7 million for the three months ended September 30, 2022. The increase in revenue was primarily driven by an increase in delivery of professional services that enable our customers to identify and implement applications that leverage our QCaaS cloud platform, partly offset by lower QCaaS revenue due to non-renewal for several customer contracts that were partially replaced with new customer contracts.
Cost of Revenue
Cost of revenue increased $0.4 million, or 58%, to $1.0 million for the three months ended September 30, 2023 as compared to $0.7 million for the three months ended September 30, 2022. The increase in cost of revenue was driven primarily by an increase in personnel related costs, including $0.3 million related to stock-based compensation expense.
36

Table of Contents
Operating Expenses
Research and Development Expenses

| Three Months Ended September 30, | Change
(In thousands, except percentages) | 2023 |  | 2022 |  | Amount |  | %
Research and development | $ | 9,459 |  |  | $ | 7,507 |  |  | $ | 1,952 |  |  | 26 | %

Research and development expenses increased by $2.0 million, or 26% to $9.5 million for the three months ended September 30, 2023 compared to $7.5 million for the three months ended September 30, 2022. The increase was primarily a result of our continuous efforts to broaden the functionality of our QCaaS cloud platform and improve the reliability, availability and scalability of our cloud platform. In particular, our personnel-related expenses increased by $2.2 million (including $2.0 million related to stock-based compensation expense). These increases were offset by decreases in facilities costs of $0.1 million and a reduction in professional fees of $0.1 million.
General and Administrative Expenses

| Three Months Ended September 30, | Change
(In thousands, except percentages) | 2023 |  | 2022 |  | Amount |  | %
General and administrative | $ | 8,003 |  |  | $ | 5,925 |  |  | $ | 2,078 |  |  | 35 | %

General and administrative expenses increased $2.1 million, or 35%, to $8.0 million for the three months ended September 30, 2023 as com pared to $5.9 million for the three months ended September 30, 2022. Our personnel-related expenses increased $2.5 million (including $2.3 million related to stock-based compensation expense), partly offset by a $1.0 million decrease in legal, audit, and other professional fees resulting from the Merger occurring in the comparable period.
Sales and Marketing Expenses

| Three Months Ended September 30, | Change
(In thousands, except percentages) | 2023 |  | 2022 |  | Amount |  | %
Sales and marketing | $ | 2,474 |  |  | $ | 2,773 |  |  | $ | (299) |  |  | (11) | %

Sales and marketing expenses decreased $0.3 million, or 11%, to $2.5 million for the three months ended September 30, 2023 as compared to $2.8 million for the three months ended September 30, 2022. The decrease was primarily a result of decreased promotional expenses of $0.3 million and professional fees of $0.1 million, offset by increased personnel costs of $0.1 million.
Other Income (Expense), net (As Restated)

| Three Months Ended September 30, | Change
| 2023 |  | 2022 |  | Amount |  | %
(In thousands, except percentages) | (As Restated) |  | (As Restated) |  |  |  |
Other income (expense), net | $ | 2,301 |  |  | $ | 3,514 |  |  | $ | (1,213) |  |  | (35) | %

Other income, net decreased by $1.2 million or 35%, to $2.3 million for the three months ended September 30, 2023 as compared to $3.5 million for the three months ended September 30, 2022. the decreases were primarily due to decreases in the change in fair value of warrant liabilities of $1.2 million, decreased foreign exchange gains of $1.2 million, and increase in debt issuance costs of $0.7 million, and an increase in interest expense of $0.4 million. These decreases were partly offset by changes in the fair value of the Term Loan of $1.7 million and decreased LPC Purchase Agreement issuance costs of $0.6 million.
37

Table of Contents
Comparison of the Nine Months Ended September 30, 2023 and 2022
Revenue
Revenue increased $1.1 million, or 22%, to $5.9 million for the nine months ended September 30, 2023 as compared to $4.8 million for the nine months ended September 30, 2022. The increase in revenue was primarily driven by an increase in delivery of professional services that enable our customers to identify and implement applications that leverage our QCaaS cloud platform, partly offset by lower QCaaS revenue due to non-renewal for several customer contracts that were partially replaced with new customer contracts.
Cost of Revenue
Cost of revenue increased $1.3 million, or 72%, to $3.2 million for the nine months ended September 30, 2023 as compared to $1.9 million for the nine months ended September 30, 2022. The increase in cost of revenue was primarily driven by an increase in personnel related costs, including $0.9 million in stock-based compensation costs.
Operating Expenses
Research and Development Expenses

| Nine Months Ended September 30, | Change
| 2023 |  | 2022 |  | Amount |  | %
Research and development | $ | 29,922 |  |  | $ | 21,799 |  |  | $ | 8,123 |  |  | 37 | %

Research and development expenses increased by $8.1 million, or 37%, to $29.9 million for the nine months ended September 30, 2023 compared to $21.8 million for the nine months ended September 30, 2022. The increase was primarily a result of our continuous efforts to broaden the functionality of our QCaaS cloud platform and improve the reliability, availability and scalability of our cloud platform. In particular, our personnel-related expenses increased $6.5 million (including $6.2 million related to stock-based compensation expense), and our wafer fabrication costs increased $0.9 million due to higher activity rates.
General and Administrative Expenses

| Nine Months Ended September 30, | Change
| 2023 |  | 2022 |  | Amount |  | %
General and administrative | $ | 28,875 |  |  | $ | 13,566 |  |  | $ | 15,309 |  |  | 113 | %

General and administrative expenses increased $15.3 million, or 113%, to $28.9 million for the nine months ended September 30, 2023 as compared to $13.6 million for the nine months ended September 30, 2022. The increase was primarily a result of operating as a public company. In particular, our legal, accounting, tax and consulting fees increased $4.4 million, our personnel-related expenses increased $8.6 million (including $6.9 million related to stock-based compensation expense), and insurance costs increased $1.4 million.
Sales and Marketing Expenses

| Nine Months Ended September 30, | Change
| 2023 |  | 2022 |  | Amount |  | %
Sales and marketing | $ | 7,862 |  |  | $ | 5,982 |  |  | $ | 1,880 |  |  | 31 | %

Sales and marketing expenses increased $1.9 million, or 31%, to $7.9 million for the nine months ended September 30, 2023 as compared to $6.0 million for the three months ended September 30, 2022. The increase was primarily a result of our efforts to expand our go-to-market initiatives. The increase was comprised of higher personnel-related expenses of $1.4 million, mainly attributed to salary and commission increases, promotional costs of $0.1 million and consulting of $0.2 million.
38

Table of Contents
Other Income (Expense), net (As Restated)

| Nine Months Ended September 30, |  | Change
| 2023 |  | 2022 |  | Amount |  | %
| (As Restated) |  | (As Restated) |  |  |  |
Other income (expense), net | $ | (2,697) |  |  | $ | 2,504 |  |  | $ | (5,201) |  |  | (208) | %

Other expense, net increased by $5.2 million or -208%, to $2.7 million for the nine months ended September 30, 2023 as compared to income of $2.5 million for the nine months ended September 30, 2022. The increases were driven by $1.5 million in increased debt and equity issuance costs, $2.6 million in unfavorable changes in the fair value of warrant liabilities, and a $2.8 million reduction in unrealized foreign exchange gains. These increases were partly offset by $1.4 million in favorable changes in fair value of the Term Loan, and a $0.4 million reduction in interest expense.
Liquidity and Capital Resources
We have incurred net losses and experienced negative cash flows from operations since inception. To date, our primary sources of capital have been through private placements of convertible preferred shares, private placements of common stock, revenue from the sale of our products and services, government assistance and debt financing. During the nine month period ended September 30, 2023 and 2022, we incurred net losses of $66.7 million and $35.9 million, respectively. We expect to incur additional losses and higher operating expenses for the foreseeable future as we continue to invest in research and development and go-to-market programs. We have determined that additional financing will be required to fund our operations for the next 12 months and our ability to continue as a going concern is dependent upon obtaining additional capital and financing.
Our primary uses of cash are to fund our operations as we continue to grow our business. We will require a significant amount of cash for expenditures as we invest in expanding our commercial organization, as well as ongoing research and development and business operations. Until such time as we can generate significant revenue from sales of our QCaaS offering and our professional services, we expect to finance our cash needs through public and/or private equity (including sales pursuant to the Purchase Agreement) and/or debt financings or other capital sources. However, we may be unable to raise sufficient funds or enter into such other arrangements, when needed, on favorable terms, or at all. In particular, uncertain and unfavorable conditions in the United States and global macroeconomic environment, including inflationary pressures, rising interest rates, banking collapses, and financial and credit market fluctuations, could reduce our ability to access capital on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce our quantum computing development and go-to-market efforts.
As of September 30, 2023, we have 17,916,606 Warrants outstanding, each Warrant being exercisable for 1.4541326 Common Shares of the Company at an exercise price of $11.50. Whether warrant holders will exercise their Warrants, and therefore the amount of cash proceeds we would receive upon exercise, is dependent upon the trading price of the Common Shares. Therefore, if and when the trading price of the Common Shares is less than approximately $7.91, the effective exercise price of the Warrants per one Common Share we expect that warrant holders will not exercise their Warrants. Our Common Shares have closed below $7.91 since October 11, 2022. Therefore, we do not expect warrant holders to exercise their Warrants in the short-term and as such we do not expect to rely on the cash exercise of Warrants to fund our operations. Instead, we intend to rely on other sources of cash discussed below to continue to fund our operations. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, or substantially reduce our quantum computing development and go-to-market efforts.
39

Table of Contents
Term Loan and Security Agreement
On April 13, 2023, we entered into the Term Loan, by and between us and PSPIB Unitas Investments II Inc. (the "Lender" or "PSPIB") as the lender. Under the Term Loan, loans in aggregate principal amount of $50.0 million are to be made available to us in three tranches, subject to certain terms and conditions and a 2.0% drawdown fee. The Term Loan matures on March 31, 2027 and is secured by a first-priority security interest in substantially all of our assets and contains certain operational and financial covenants, including a financial covenant that measures our revenue against certain minimum percentages of budgeted revenue per quarter. The Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10.0% of the amount then prepaid to the Lender, except as modified by the amendment to the Term Loan as described below. The Term Loan is subject to a prepayment premium due to the Lender equal to 3% of the amount prepaid/repaid within the first year of the Closing Date, 2% in the second year, 1% in the third year and no prepayment premium thereafter. At our discretion, the Term Loan bears interest on a monthly basis at either (i) 10.0% payable in cash, or (ii) 11.0% payable in kind (PIK), with the latter added to the principal value of the Term Loan.
The first two tranches of the Term Loan, each amounting to $15.0 million in principal, were advanced to us on April 14, 2023 and July 13, 2023, respectively, with the third tranche of $20.0 million to be made automatically available subject to the satisfaction of certain conditions. Prior to PSPIB's advance of the first tranche, the Company satisfied several closing conditions including the provision of a cash flow forecast and the board of directors' retention of an advisor. The Lender agreed to modify certain conditions to the funding of the second tranche of the Term Loan, including delaying the delivery of a board-approved operating budget and plan for the Company’s fiscal years 2023 through 2027 to August 31, 2023 (later extended to December 31, 2023); modifying the condition that, prior to the funding of the second tranche, the Company shall have nominated an additional director that is either an employee of PSPIB or an independent director selected from PSPIB nominees to require such appointment at a later time at PSPIB’s option; and modifying notice deadline requirements for the registration or filings of intellectual property. PSPIB has also agreed to waive certain covenants under the Term Loan that the Company did not meet, including the minimum revenue financial covenant for the second and third fiscal quarters ended June 30, 2023 and September 30, 2023, respectively. The second tranche was advanced to us after we satisfied several closing conditions, including providing the Lender with an intellectual property valuation report and SIF’s consent to the grant of security interests in D-Wave's project intellectual property associated with the SIF Loan. There can be no as surance that the Company will be able to meet the conditions necessary to draw on the third tranche or will be able to comply with the covenants of the Term Loan, or that PSPIB will agree to waive covenants under the Term Loan in the future. The availability of the third tranche is subject to us closing a $25.0 million non-dilutive financing on terms reasonably acceptable to the Lender, the intellectual property valuation report submitted as a condition precedent to the second tranche remaining satisfactory to the Lender and providing a board-approved operating budget for 2023 through 2027 by December 31, 2023 that is satisfactory to the Lender.
The Term Loan was amended on July 20, 2023 such that the Company may issue up to $50.0 million under the Lincoln Park Purchase Agreement described below without the requirement to pay down the Term Loan to the extent that the proceeds under the Purchase Agreement are received prior to October 18, 2023. As amended, the Term Loan requires that any proceeds from the issuance of Common Shares under the Purchase Agreement in excess of $50.0 million shall be applied towards the repayment of advances under the Term Loan in addition to a premium payment equal to 10% of the amount then prepaid to the Lender.
On October 6, 2023 the Company entered into the fourth amendment to the Term Loan. Under the amendment, the deadline for the Company to deliver to PSPIB a board-approved operating budget and plan for the Company's fiscal years 2023 through 2027 was extended to December 31, 2023. In addition, the amendment extended the period for which no prepayment of the advances under the Term Loan is required with respect to aggregate gross proceeds of up to $50.0 million the Company receives pursuant to share issuances under the Purchase Agreement to the extent proceeds are received prior to December 31, 2023.
40

Table of Contents
Lincoln Park Purchase Agreement
The Purchase Agreement with Lincoln Park may provide the Company with additional liquidity to fund the business, subject to the conditions set forth in the agreement, including volume limitations tied to periodic market prices, ownership limitations restricting Lincoln Park from owning more than 9.9% of the then total outstanding Common Shares and a floor price of $1.00 at which the Company may not sell to Lincoln Park any Common Shares. When we sell shares to Lincoln Park, Lincoln Park may resell all, some, or none of those Common Shares at any time or from time to time in its discretion. For the nine months ended September 30, 2023, the Company has received $61.3 million in proceeds through the issuance of 39,487,104 Common Shares to Lincoln Park under the Purchase Agreement. In order for the Company to issue Common Shares under the Purchase Agreement, the Company's share price must be above the floor price of $1.00 per share. Since October 11, 2023, the price of our Common Shares has closed below the $1.00 floor price. We may not sell any Common Shares to Lincoln Park unless and until the price of our Common Shares subsequently exceeds the $1.00 floor price. There is no assurance that the price of our Common Shares will exceed $1.00, which will affect our ability to generate proceeds under the Purchase Agreement.
To the extent that sufficient capital is not obtained through the cash received in connection with the Term Loan and the issuance of Common Shares under the Purchase Agreement, management will be required to obtain additional capital through the issuance of additional debt and/or equity, or other arrangements. However, there can be no assurance that D-Wave will be able to raise additional capital when needed or under acceptable terms, especially if D-Wave fails to maintain the listing of its Common Shares on the NYSE. The issuance of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to the currently outstanding Common Shares. Any future debt may contain covenants and limit D-Wave’s ability to pay dividends or make other distributions to stockholders.
Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled “Risk Factors" in this Report.
Cash Flows (As Restated)
The following table sets forth our cash flows for the periods indicated (in thousands):

| Nine months ended September 30,
| 2023 |  | 2022
| (As Restated) |  | (As Restated)
Net cash (used in) provided by: |  |  |
Operating Activities | $ | (45,910) |  |  | $ | (34,339) |
Investing Activities | (176) |  |  | (316) |
Financing Activities | 92,408 |  |  | 38,967 |
Effect of exchange rate changes on cash and cash equivalents | (70) |  |  | (31) |
Net increase in cash and cash equivalents | $ | 46,252 |  |  | $ | 4,281 |

Cash Flows Used in Operating Activities
Our cash flows from operating activities are significantly affected by the growth of our business, and are primarily related to research and development, sales and marketing and general and administrative activities. Our operating cash flows are also affected by our working capital needs to support growth in personnel-related expenditures and fluctuations in accounts payable, accounts receivable and other current assets and liabilities.
Net cash used in operating activities during the nine months ended September 30, 2023 was $45.9 million, resulting primarily from a net loss of $66.7 million, adjusted for non-cash charges of $1.4 million in depreciation and amortization, including amortization of operating right of use assets, $17.4 million in stock-based compensation, $1.0 million of debt issuance costs for the Term Loan, $0.1 million in change in fair value of public and private warrants, $1.7 million in non-cash interest and $0.6 million in working capital adjustments, which was partially offset by $1.4 million increase in fair value of Term Loan.
Net cash used in operating activities during the nine months ended September 30, 2022 was $34.3 million, resulting primarily from a net loss of $35.9 million, adjusted for non-cash charges of $1.5 million in depreciation and amortization including amortization of operating right of use assets, $3.4 million in stock-based compensation, $0.3 million in non-cash interest on government loans, $0.3 million in other non-cash activities and $1.0 million in working capital adjustments.
41

Table of Contents
Cash Flows Used in Investing Activities
Net cash used in investing activities during the nine months ended September 30, 2023 was $0.2 million, primarily representing additions of $0.1 million in property and equipment.
Net cash used in investing activities during the nine months ended September 30, 2022 was $0.3 million, primarily representing additions of $0.2 million in property and equipment.
Cash Flows Provided by Financing Activities
Net cash provided by financing activities during the nine months ended September 30, 2023 w as $92.4 million, primarily reflecting proceeds from the Lincoln Park Purchase Agreement of $61.3 million, net proceeds from the first and second tranches of the Term Loan of $29.0 million, proceeds from government assistance of $1.5 million and stock option exercise proceeds of $1.9 million, partially offset by payments for financed Directors and Officers Insurance premiums of $1.4 million.
Net cash provided by financing activities during the nine months ended September 30, 2022 was $39.0 million, primarily reflecting net proceeds received from the Venture Loan and Security Agreement, dated as of March 3, 2022, between D-Wave and its subsidiaries and PSPIB, as lender, for $19.9 million, and net proceeds received from the SIF Loan for $3.1 million.
Contractual Obligations and Commitments
As of September 30, 2023, there have been no material changes with regard to contractual obligations from those disclosed in our "Management's Discussion and Analysis on Financial Condition and Results of Operations—Contractual Obligations and Commitments" in our Annual Report on Form 10-K/A for the year ended December 31, 2022.
Critical Accounting Policies and Estimates
There have been no material changes to our critical accounting policies from those disclosed in our "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates" in our Annual Report on Form 10-K/A for the year ended December 31, 2022.
Recent Accounting Pronouncements
See Note 2 of our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q/A for more information regarding recently issued accounting pronouncements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable to Smaller Reporting Companies.
Item 4. Controls and Procedures
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Evaluation of Disclosure Controls and Procedures
In accordance with the Exchange Act Rules 13a-15(e) and 15d-15(e), we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, due to a material weakness in our internal control over financial reporting specifically related to D-Wave’s control environment in relation to our financial statement close process (i.e., lack of sufficient accounting and financial reporting personnel with requisite knowledge and experience in the application of complex areas of GAAP and SEC rules to facilitate accurate and timely financial reporting and to perform sufficient review over certain financial statement areas), as previously disclosed in Item 9A of our Annual Report on Form 10-K/A for the year ended December 31, 2022, our disclosure controls and procedures were not effective as of the end of the period covered by this Report.
42

Table of Contents
Notwithstanding the material weakness described above, we have concluded that our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q/A are fairly stated in all material respects in accordance with U.S. GAAP for the periods presented therein.
Remediation Efforts on Previously Reported Material Weakness
We are implementing measures designed to improve our internal controls over financial reporting to remediate this material weakness including adding additional qualified accounting personnel with experience with complex GAAP and SEC rules, engaging consultants to assist with the financial statement close process, and segregating duties among accounting personnel to enable adequate review controls. The primary costs associated with such measures are corresponding recruiting and additional salary and consulting costs, which are difficult to estimate at this time but which may be significant. These additional resources and procedures are intended to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal control procedures.
The material weakness will not be considered remediated until our remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively. We are continuing to work on the implementation of our remediation plan, following which we will continue to test such controls over time.
Changes in Internal Control Over Financial Reporting
Other than the ongoing remediation to address the material weakness described above, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), during the three months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
43

Table of Contents
Part II - Other Information
Item 1. Legal Proceedings
To the knowledge of our management, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.
From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.
Item 1A. Risk Factors
There have been no material changes from the risk factors set forth in our Annual Report on Form 10-K/A for the year ended December 31, 2022, as filed with the SEC on March 15, 2024, with the exception of the risk factor discussed below.
If we are unable for any reason to meet the continued listing requirements of the NYSE, such action or inaction could result in a delisting of our securities.
On October 20, 2023, we were notified by the NYSE that we are not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our Common Shares was less than $1.00 over a consecutive 30 trading-day period. The notice had no immediate impact on the listing of our Common Shares, which will continue to be listed and traded on the NYSE during the period allowed to regain compliance, subject to our compliance with other listing standards. On October 24, 2023, we notified the NYSE that we intend to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. We can regain compliance at any time within the six-month period following receipt of the NYSE notice if on the last trading day of any calendar month during the cure period our Common Shares have a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE’s rules, if we determine that we will cure the stock price deficiency by taking an action that will require stockholder approval at our next annual meeting of stockholders, the price condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days.
The delisting of our Common Shares from the NYSE will likely make it more difficult for us to raise capital on favorable terms in the future. Such a delisting would likely have a negative effect on the price of our securities and would impair your ability to sell or purchase our securities when you wish to do so. In the event of a delisting, actions taken by us to restore compliance with listing requirements may not allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent such securities from dropping below any minimum bid price requirement or prevent future non-compliance with the NYSE listing requirements.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On November 7, 2023, after nearly 9 years at D-Wave, Victoria Brydon, Chief People Officer, provided her resignation letter and will be leaving the Company as of December 13, 2023.
44

Table of Contents
Item 6. Exhibits

Exhibit No. | Description | Incorporated by Reference Exhibits
|  | Filer | Form | Exhibit | Filing Date
10.1 | Limited Waiver and Second Amendment to Loan and Security Agreement, dated as of July 13, 2023, by and among PSPIB Unitas Investments II Inc. and D-Wave Quantum Inc. | D-Wave Quantum Inc. | 8-K | 10.1 | July 20, 2023
10.2 | Third Amendment to Loan and Security Agreement, dated as of July 20, 2023, by and among PSPIB Unitas Investments II Inc. and D-Wave Quantum Inc. | D-Wave Quantum Inc. | 8-K | 10.1 | July 21, 2023
10.3 | Limited Waiver to Loan and Security Agreement, dated as of July 28, 2023, by and between D-Wave Quantum Inc. and PSPIB Unitas Investments II Inc. | D-Wave Quantum Inc. | 10-Q | 10.7 | August 10, 2023
10.4† | Promotion Letter between Diane Nguyen and D-Wave Commercial Inc., dated July 10, 2023. | D-Wave Quantum Inc. | 10-Q | 10.13 | August 10, 2023
10.5† | Amendment to Full-Time Employment Agreement, between Victoria Brydon and D-Wave Systems Inc., dated July 10, 2023. | D-Wave Quantum Inc. | 10-Q | 10.14 | August 10, 2023
10.6* | Limited Waiver to Loan and Security Agreement, dated as of November 7, 2023, by and between D-Wave Quantum Inc. and PSPIB Unitas Investments II Inc. |  |  |  |
31.1* | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |
31.2* | Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |
32.1#* | Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |
32.2#* | Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |
101.INS * | Inline XBRL Instance Document |  |  |  |
101.SCH * | Inline XBRL Taxonomy Schema Document |  |  |  |
101.CAL * | Inline XBRL Taxonomy Calculation Linkbase Document |  |  |  |
101.DEF * | Inline XBRL Taxonomy Definition Linkbase Document |  |  |  |
101.LAB * | Inline XBRL Taxonomy Label Linkbase Document |  |  |  |
101.PRE * | Inline XBRL Taxonomy Presentation Linkbase Document |  |  |  |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |  |  |  |

* Filed herewith.
# The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q/A are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q/A, irrespective of any general incorporation language contained in such filing.
† Indicates management contract or compensatory plan or arrangement.
45

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| D-Wave Quantum Inc.
March 15, 2024 | By: | /s/ John M. Markovich
|  | John M. Markovich
|  | Chief Financial Officer
|  | (Principal Financial and Accounting Officer)

46